<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">107538</article-id>
<article-id pub-id-type="doi">10.7554/eLife.107538</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.107538.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.2</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Chromosomes and Gene Expression</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Cancer Biology</subject>
</subj-group>
</article-categories><title-group>
<article-title>p53-induced RNA-binding protein ZMAT3 inhibits transcription of a hexokinase to suppress mitochondrial respiration</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kumar</surname>
<given-names>Ravi</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Couly</surname>
<given-names>Simon</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Muys</surname>
<given-names>Bruna R</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Xiao Ling</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8455-1584</contrib-id>
<name>
<surname>Grammatikakis</surname>
<given-names>Ioannis</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Singh</surname>
<given-names>Ragini</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guest</surname>
<given-names>Mary</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wen</surname>
<given-names>Xinyu</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tang</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ambs</surname>
<given-names>Stefan</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1245-1338</contrib-id>
<name>
<surname>Jenkins</surname>
<given-names>Lisa M</given-names>
</name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pehrsson</surname>
<given-names>Erica C</given-names>
</name>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chari</surname>
<given-names>Raj</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Su</surname>
<given-names>Tsung-Ping</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4299-8177</contrib-id>
<name>
<surname>Lal</surname>
<given-names>Ashish</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<email>ashish.lal@nih.gov</email>
</contrib>
    <aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05bjen692</institution-id><institution>Regulatory RNAs and Cancer Section, Genetics Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH)</institution></institution-wrap>, <city>Bethesda</city>, <country country="US">United States</country></aff>
    <aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00fq5cm18</institution-id><institution>Cellular Pathobiology Section, Integrative Neuroscience Branch, National Institute on Drug Abuse (NIDA), NIH</institution></institution-wrap>, <city>Baltimore</city>, <country country="US">United States</country></aff>
    <aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v6m3209</institution-id><institution>Genome Modification Core, Frederick National Lab for Cancer Research, NCI, NIH</institution></institution-wrap>, <city>Frederick</city>, <country country="US">United States</country></aff>
    <aff id="a4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05bjen692</institution-id><institution>Oncogenomics Section, Genetics Branch, CCR, NCI, NIH</institution></institution-wrap>, <city>Bethesda</city>, <country country="US">United States</country></aff>
    <aff id="a5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05bjen692</institution-id><institution>Laboratory of Human Carcinogenesis, CCR, NCI, NIH</institution></institution-wrap>, <city>Bethesda</city>, <country country="US">United States</country></aff>
    <aff id="a6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05bjen692</institution-id><institution>Mass Spectrometry Section, Laboratory of Cell Biology, CCR, NCI, NIH</institution></institution-wrap>, <city>Bethesda</city>, <country country="US">United States</country></aff>
    <aff id="a7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v6m3209</institution-id><institution>Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research</institution></institution-wrap>, <city>Frederick</city>, <country country="US">United States</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Hu</surname>
<given-names>Wenwei</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/05vt9qd57</institution-id><institution>Rutgers, The State University of New Jersey</institution>
</institution-wrap>
<city>New Brunswick</city>
<country country="US">United States</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Cooper</surname>
<given-names>Jonathan A</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutch Cancer Center</institution>
</institution-wrap>
<city>Seattle</city>
<country country="US">United States</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="coi-statement"><p>Competing interests: No competing interests declared</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2025-06-26">
<day>26</day>
<month>06</month>
<year>2025</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2026-01-19">
<day>19</day>
<month>01</month>
<year>2026</year>
</pub-date>
<volume>14</volume>
<elocation-id>RP107538</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2025-05-09">
<day>09</day>
<month>05</month>
<year>2025</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2025-05-13">
<day>13</day>
<month>05</month>
<year>2025</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2025.05.12.653341"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2025-06-26">
<day>26</day>
<month>06</month>
<year>2025</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.107538.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.107538.1.sa3">eLife Assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.107538.1.sa2">Reviewer #1 (Public review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.107538.1.sa1">Reviewer #2 (Public review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.107538.1.sa0">Reviewer #3 (Public review):</self-uri>
</event>
</pub-history>
<permissions>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">
<ali:license_ref>https://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref>
<license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-107538-v2.pdf"/>
<abstract><p>The tumor suppressor p53 is a transcription factor that controls the expression of hundreds of genes. Emerging evidence indicates that the p53-induced RNA-binding protein ZMAT3 acts as a key splicing regulator that contributes to p53-dependent tumor suppression in vitro and in vivo. However, the mechanism by which ZMAT3 functions within the p53 pathway remains largely unclear. Here, we discovered a function of ZMAT3 in inhibiting transcription of <italic>HKDC1</italic>, a hexokinase that regulates glucose metabolism and mitochondrial respiration. Quantitative proteomics revealed HKDC1 as the most significantly upregulated protein in <italic>ZMAT3</italic>-depleted colorectal cancer cells. <italic>ZMAT3</italic> depletion resulted in increased mitochondrial respiration, which was rescued by simultaneous depletion of <italic>HKDC1</italic>, suggesting that HKDC1 is a critical downstream effector of <italic>ZMAT3</italic>. Unexpectedly, ZMAT3 did not bind to <italic>HKDC1</italic> RNA or DNA; however, proteomic analysis of the ZMAT3 interactome identified its interaction with the oncogenic transcription factor JUN. ZMAT3 depletion enhanced JUN binding to the <italic>HKDC1</italic> locus, leading to increased <italic>HKDC1</italic> transcription that was rescued upon JUN depletion, suggesting that JUN activates <italic>HKDC1</italic> transcription in ZMAT3-depleted cells. Collectively, these findings uncover a mechanism by which ZMAT3 regulates transcription through JUN and demonstrate that <italic>HKDC1</italic> is a key component of the ZMAT3-regulated transcriptome in the context of mitochondrial respiration regulation.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Key words</title>
<kwd>p53</kwd>
<kwd>ZMAT3</kwd>
<kwd>HKDC1</kwd>
<kwd>JUN</kwd>
<kwd>RNA-binding protein</kwd>
<kwd>hexokinase</kwd>
<kwd>mitochondrial respiration</kwd>
<kwd>metabolism</kwd>
<kwd>proliferation</kwd>
<kwd>proteomics</kwd>
<kwd>transcription</kwd>
<kwd>tumor suppressor</kwd>
<kwd>cancer</kwd>
</kwd-group>
<funding-group>
<award-group id="funding-1">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/040gcmg81</institution-id>
<institution>National Cancer Institute</institution>
</institution-wrap>
</funding-source>
<award-id>ZIA BC011646</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Figures 1-5 revised, Supplemental files updated</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p><italic>TP53</italic> is the most frequently mutated gene in human cancer and functions as a major tumor suppressor<sup><xref ref-type="bibr" rid="c1">1</xref></sup>. <italic>TP53</italic> mutations in the germLine of Li Fraumeni patients and in sporadic cancer, are mostly missense mutations that occur in the DNA-binding domain resulting in loss of tumor suppressor function and in some cases, gain of oncogenic functions<sup><xref ref-type="bibr" rid="c2">2</xref>–<xref ref-type="bibr" rid="c4">4</xref></sup>. Deletion of the <italic>Trp53</italic> gene in mice results in spontaneous tumor development within 6 months of age at 100% penetrance, underscoring the importance of p53 as a tumor suppressor<sup><xref ref-type="bibr" rid="c5">5</xref>,<xref ref-type="bibr" rid="c6">6</xref></sup>. Mechanistically, p53 functions as a sequence-specific transcription factor activating the expression of hundreds of genes that control diverse cellular processes including but not limited to, cell cycle arrest, apoptosis, senescence and DNA repair<sup><xref ref-type="bibr" rid="c7">7</xref>,<xref ref-type="bibr" rid="c8">8</xref></sup>. Despite the undisputed role of p53 in tumor suppression, our understanding of how p53 target genes mediate the effects of p53 is not fully understood.</p>
<p>Among the p53 target genes, some such as <italic>p21</italic> (<italic>CDKN1A</italic>) control p53-dependent cell cycle arrest, whereas <italic>PUMA</italic> and <italic>NOXA</italic> are critical in inducing apoptosis downstream of p53<sup><xref ref-type="bibr" rid="c9">9</xref>–<xref ref-type="bibr" rid="c11">11</xref></sup>. <italic>In vivo</italic> studies in mice have demonstrated that <italic>Abca1</italic>, <italic>Gls2</italic>, <italic>MLh1</italic>, <italic>Padi4</italic> and <italic>Zmat3</italic> play key roles in mediating the tumor suppressor effects of p53<sup><xref ref-type="bibr" rid="c12">12</xref>–<xref ref-type="bibr" rid="c15">15</xref></sup>. However, triple knockout mice lacking <italic>p21</italic>, <italic>Puma</italic> and <italic>Noxa</italic>, which are regulators of cell cycle arrest and apoptosis in the p53 pathway, do not develop tumors spontaneously, unlike p53 null mice<sup><xref ref-type="bibr" rid="c16">16</xref></sup>. This has led to search for new mechanisms and effectors of p53-mediated tumor suppression.</p>
<p>An emerging potent mediator of p53 is the p53 target gene <italic>ZMAT3</italic>, which functions as an RNA-binding protein and studies in mice strongly implicate <italic>Zmat3</italic> as a tumor suppressor<sup><xref ref-type="bibr" rid="c17">17</xref>–<xref ref-type="bibr" rid="c19">19</xref></sup>. Mechanistically, using transcriptome-wide approaches from crosslinked cells, we and others recently reported that ZMAT3 directly binds to intronic sequences in thousands of pre-mRNAs and regulates alternative splicing<sup><xref ref-type="bibr" rid="c17">17</xref>,<xref ref-type="bibr" rid="c20">20</xref></sup>. ZMAT3 has also been shown to interact with AU-rich elements in the 3′ untranslated regions (UTR) of target mRNAs either stabilizing its targets or promoting their decay<sup><xref ref-type="bibr" rid="c21">21</xref>–<xref ref-type="bibr" rid="c24">24</xref></sup>. A deeper understanding of the molecular mechanisms by which ZMAT3 functions is necessary to better understand how ZMAT3 functions in p53-mediated tumor suppression.</p>
<p>Here, to better understand the function of ZMAT3, we identified the ZMAT3-interactome and the proteins regulated by ZMAT3. Unexpectedly, this approach revealed that ZMAT3 inhibits mitochondrial respiration by interacting with the transcription factor JUN (c-Jun) to inhibit transcription of the hexokinase <italic>HKDC1</italic> (hexokinase domain containing 1). We focused on <italic>HKDC1</italic> because by quantitative proteomics, HKDC1 was the most strongly up-regulated protein in ZMAT3-depleted colorectal cancer (CRC) cells. Hexokinases are the first rate-limiting enzymes in the glucose metabolic pathway that phosphorylate glucose to glucose-6-phosphate and thereby modulate glycolysis, oxidative phosphorylation, and the pentose phosphate pathway. There are four classic hexokinases (HK1-4), and recently HKDC1 was identified as the fifth hexokinase<sup><xref ref-type="bibr" rid="c25">25</xref></sup>. Besides its hexokinase function, HKDC1 also interacts with the mitochondrial membrane to maintain mitochondrial homeostasis and plays an important role in preventing cellular senescence<sup><xref ref-type="bibr" rid="c26">26</xref>–<xref ref-type="bibr" rid="c28">28</xref></sup>. Although HKDC1 is reported to be overexpressed in many cancers and high HKDC1 expression is associated with poor clinical outcome<sup><xref ref-type="bibr" rid="c27">27</xref>–<xref ref-type="bibr" rid="c30">30</xref></sup>, how HKDC1 expression is regulated remains largely unclear. Our findings provide novel insights on the regulation and function of HKDC1 in the p53 pathway via transcriptional inhibition by a ZMAT3/JUN axis.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>The hexokinase HKDC1 is the most strongly upregulated protein in ZMAT3-knockout cells</title>
<p>To investigate the mechanism by which ZMAT3 promotes growth suppression, we utilized CRISPR/Cas9 to deplete ZMAT3 in HCT116 cells (CRC) using two sgRNAs flanking the p53 response element (RE) in the second intron of <italic>ZMAT3</italic>. The rationale for deleting the p53RE was based on previous data showing that p53RE of the <italic>ZMAT3</italic> gene is critical for ZMAT3 expression<sup><xref ref-type="bibr" rid="c20">20</xref></sup>. Deleting the p53RE should therefore result in a marked decrease in ZMAT3 expression without disrupting the entire <italic>ZMAT3</italic> locus. Although this approach did not completely delete the region spanning the two sgRNAs, a ∼57 bp region near sgRNA#1 was deleted resulting in &gt;75% decrease in <italic>ZMAT3</italic> mRNA levels (<xref rid="fig1" ref-type="fig">Figure 1A</xref> and <xref rid="fig1" ref-type="fig">B</xref>). At the protein level, ZMAT3 was strongly induced only in <italic>ZMAT3</italic>-WT (wild-type) cells upon treatment with Nutlin, a small molecule that upregulates p53 and its target genes (Figure 1- figure supplement 1A). As expected, upon Nutlin treatment, p53 and its canonical target p21, were induced to similar levels in <italic>ZMAT3</italic>-WT and isogenic <italic>ZMAT3</italic>-KO (knockout) cells (Figure 1-figure supplement 1A). Depletion of ZMAT3 resulted in increased proliferation and clonogenicity, consistent with previous reports (<xref rid="fig1" ref-type="fig">Figure 1C</xref> and Figure 1-figure supplement 1B)<sup><xref ref-type="bibr" rid="c18">18</xref>–<xref ref-type="bibr" rid="c20">20</xref></sup>.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>ZMAT3 depletion results in increased expression of genes related to glucose metabolism in colorectal cancer cells.</title>
<p><bold>(A)</bold> IGV snapshot showing the location of the two sgRNAs used to generate <italic>ZMAT3</italic>-KO HCT116 cells, the observed 57 bp deletion near sgRNA#2, and the p53 ChIP-seq peak in the <italic>ZMAT3</italic> locus in response to p53 activation upon Nutlin treatment. The p53 ChIP-seq data were previously published<sup><xref ref-type="bibr" rid="c71">71</xref></sup>. <bold>(B)</bold> RT-qPCR analysis of <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells from 3 biological replicates. <italic>GAPDH</italic> served as the housekeeping gene control. <bold>(C)</bold> Colony formation assays performed from <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells in 3 biological replicates. <bold>(D)</bold> Notched box plot of the log<sub>2</sub>fold change (FC) in RNA abundance of differentially expressed genes from RNA-Seq of <italic>ZMAT3</italic>-KO and <italic>ZMAT3</italic>-WT HCT116 cells. Median values for each group are indicated at the top of each box, and the number of RNAs for which data were obtained for each group is indicated at the bottom. <bold>(E)</bold> Volcano plot showing differentially expressed proteins (shown in red) identified by global quantitative proteomics from <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells. <bold>(F)</bold> Most significantly enriched pathways identified by GSEA of genes significantly upregulated (p&lt;0.05) in the <italic>ZMAT3</italic>-KO versus <italic>ZMAT3</italic>-WT based on quantitative proteomics data. <bold>(G)</bold> TMT mass spectrometry peptide abundance of HKDC1 in <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells. Values represent the average of five biological replicates for <italic>ZMAT3</italic>-WT and four biological replicates for <italic>ZMAT3</italic>-KO cells. <bold>(H)</bold> IGV snapshot showing <italic>ZMAT3</italic> and <italic>HKDC1</italic> transcripts from RNA-seq of <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells. ∗p &lt; 0.05, ∗∗∗∗p &lt; 0.0001.</p></caption>
<graphic xlink:href="653341v2_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>To identify the genes regulated by ZMAT3, we next performed RNA-seq from biological triplicates of <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells. As expected, <italic>ZMAT3</italic> mRNA levels significantly decreased (∼7.5-fold) in <italic>ZMAT3</italic>-KO cells (Table S1); the recently identified ZMAT3 target gene <italic>MDM4</italic><sup><xref ref-type="bibr" rid="c17">17</xref></sup> was modestly but significantly upregulated in <italic>ZMAT3</italic>-KO cells (Table S1). Transcriptome-wide, upon loss of ZMAT3, 606 genes were significantly up-regulated (adj. p&lt;0.05 and 1.5-fold change) and 552 were down-regulated with a median fold change of 1.76 and 0.55 for the up- and downregulated genes, respectively (<xref rid="fig1" ref-type="fig">Figure 1D</xref> and Table S1). Because we and others recently reported that ZMAT3 directly regulates alternative splicing<sup><xref ref-type="bibr" rid="c17">17</xref>,<xref ref-type="bibr" rid="c20">20</xref></sup>, we reasoned that ZMAT3-dependent changes in splicing could lead to altered protein levels without altering mRNA levels. We therefore performed global quantitative proteomics from <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells. At the protein level 228 proteins were significantly (p&lt;0.05) up-regulated and 108 were down-regulated upon loss of ZMAT3 (<xref rid="fig1" ref-type="fig">Figure 1E</xref>) (Table S2).</p>
<p>ZMAT3 directly binds to intronic sequences in pre-mRNAs and can inhibit inclusion of the neighboring exon<sup><xref ref-type="bibr" rid="c17">17</xref>,<xref ref-type="bibr" rid="c20">20</xref></sup>. Depletion of ZMAT3 can therefore result in increased target gene expression. Gene set enrichment analysis (GSEA) for the proteins upregulated in <italic>ZMAT3</italic>-KO cells revealed glycolysis as the most significantly overrepresented biological process (<xref rid="fig1" ref-type="fig">Figure 1F</xref>). GSEA analysis from our RNA-seq data showed that glycolysis was among the top 10 overrepresented biological processes for the mRNAs upregulated in <italic>ZMAT3</italic>-KO cells (Figure 1-figure supplement 1C). Interestingly, the most strongly upregulated protein in <italic>ZMAT3</italic>-KO cells was the hexokinase HKDC1 (∼3.4-fold, p&lt;0.05) (<xref rid="fig1" ref-type="fig">Figure 1E, G</xref> and Table S2). The increase in <italic>HKDC1</italic> expression was also observed at the mRNA level; <italic>ZMAT3</italic> mRNA downregulation in <italic>ZMAT3</italic>-KO cells served as positive control (<xref rid="fig1" ref-type="fig">Figure 1H</xref>, Figure 1-figure supplement 1D and Table S1). We therefore chose to focus on <italic>HKDC1</italic> because it was the most strongly upregulated protein upon loss of ZMAT3 and is directly involved in regulating glucose metabolism and mitochondrial respiration that are cellular processes not been previously associated with ZMAT3.</p>
</sec>
<sec id="s2b">
<title>Inhibition of <italic>HKDC1</italic> expression by ZMAT3 is conserved and observed across diverse cell types</title>
<p>To validate inhibition of <italic>HKDC1</italic> expression by ZMAT3, we next performed RT-qPCR from <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells. We observed ∼4-fold upregulation of <italic>HKDC1</italic> mRNA upon <italic>ZMAT3</italic> depletion (<xref rid="fig2" ref-type="fig">Figure 2A</xref>). This upregulation was further confirmed at the protein level by immunoblotting (<xref rid="fig2" ref-type="fig">Figure 2B</xref>). Because these experiments were conducted from a single <italic>ZMAT3</italic>-KO clone, we next analyzed our recently published RNA-seq data<sup><xref ref-type="bibr" rid="c20">20</xref></sup> conducted in biological triplicates from HCT116 cells transfected with a control siRNA (siCTRL) or <italic>ZMAT3</italic> siRNAs (SMARTpool of 4 siRNAs). <italic>ZMAT3</italic> mRNA was strongly down-regulated, whereas <italic>HKDC1</italic> mRNA was modestly but significantly up-regulated (Figure 2-figure supplement 1A and Table S3), a result that was validated by RT-qPCR (<xref rid="fig2" ref-type="fig">Figure 2C</xref>). GSEA for the mRNAs up-regulated upon <italic>ZMAT3</italic> knockdown revealed that glycolysis was among the top 10 over-represented biological processes (Figure 2-figure supplement 1B). Additionally, comparison of the RNA-seq data from the <italic>ZMAT3</italic>-WT vs <italic>ZMAT3</italic>-KO HCT116 and CTRL siRNA vs <italic>ZMAT3</italic> siRNA transfected HCT116 cells, indicated that 1023 genes were commonly up-regulated (p&lt;0.05 and log<sub>2</sub>fold change&gt;0), and 1042 genes were commonly down-regulated (p&lt;0.05 and log<sub>2</sub>fold change&lt;0) upon loss of ZMAT3 (Figure 2-figure supplement 1C and D), suggesting that <italic>ZMAT3</italic> depletion results in altered expression of thousands of genes. GSEA analysis for the top 500 mRNAs up-regulated upon <italic>ZMAT3</italic> knockdown showed that glycolysis was among the top 10 over-represented biological processes (Figure 2- figure supplement 1E). It should be noted that for the comparison of both RNA-seq datasets (<italic>ZMAT3</italic>-WT vs <italic>ZMAT3</italic>-KO and siCTRL vs. siZMAT3), we included genes that were consistently up- or down-regulated, without applying a fold change threshold, focusing instead on significantly altered genes (p&lt;0.05) in both datasets. This allowed us to capture broader and more reproducible transcriptomic changes that occur upon <italic>ZMAT3</italic> depletion, including modest but significant changes.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title>ZMAT3 negatively regulates <italic>HKDC1</italic> expression in diverse cell types.</title>
<p><bold>(A, B)</bold> RT-qPCR and immunoblotting for HKDC1 in <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells. GAPDH served as the housekeeping gene control. RT-qPCR was performed in biological triplicates. <bold>(C, D)</bold> RT-qPCR analysis from the indicated cell lines in biological triplicates following transfection with control (CTRL) siRNA or <italic>ZMAT3</italic> siRNAs for 72 h. <italic>GAPDH</italic> served as the housekeeping gene control. <bold>(E)</bold> Immunoblotting of whole-cell lysates from HCT116 and HepG2 cells after siRNA-mediated knockdown of <italic>ZMAT3</italic> or <italic>HKDC1</italic> for 72 h. GAPDH served as the loading control. <bold>(F)</bold> Fold change in <italic>Zmat3, Trp53, Mdm4</italic> and <italic>Hkdc1</italic> mRNA levels from RNA-seq analysis of <italic>Zmat3</italic> knockout and wild-type MEFs. (<bold>G)</bold> Analysis of <italic>HKDC1</italic> mRNA levels in normal colon tissue and CRC samples from the TCGA COAD cohort. N indicates the number of samples in each group. <bold>(H)</bold> Fold change in <italic>Trp53, Zmat3, Cdkn1a</italic> and <italic>Hkdc1</italic> mRNA levels from RNA-seq analysis of <italic>Trp53</italic> knockout and wild-type MEFs. ∗p &lt; 0.05, ∗∗p &lt; 0.01, ∗∗∗p &lt; 0.001, ∗∗∗∗p &lt; 0.0001</p></caption>
<graphic xlink:href="653341v2_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>To determine if ZMAT3 inhibits <italic>HKDC1</italic> expression across diverse cell types, we performed RT-qPCR after <italic>ZMAT3</italic> knockdown in SW1222 (CRC cells), HCEC-1CT (immortalized human colonic epithelial cells), and HepG2 (liver cancer cells). We observed significant increase in <italic>HKDC1</italic> mRNA levels upon <italic>ZMAT3</italic> knockdown in these cell lines (<xref rid="fig2" ref-type="fig">Figure 2D</xref>). At the protein level, we HKDC1 levels increased upon <italic>ZMAT3</italic> knockdown in HCT116, HepG2, SW1222 and HCEC-1CT cells (<xref rid="fig2" ref-type="fig">Figure 2E</xref>, Figure 2-figure supplement 1F and G). To determine whether this regulatory relationship is conserved between human and mouse, we analyzed recently published RNA-seq data from <italic>Zmat3</italic> knockout mouse embryonic fibroblasts (MEFs)<sup><xref ref-type="bibr" rid="c31">31</xref></sup>. <italic>Hkdc1</italic> mRNA was significantly up-regulated (∼6-fold) in <italic>Zmat3</italic>-KO MEFs (<xref rid="fig2" ref-type="fig">Figure 2F</xref>). As expected, we observed a decrease in <italic>Zmat3</italic> mRNA, upregulation of the <italic>Zmat3</italic>-target gene <italic>Mdm4</italic> and no changes in <italic>Trp53</italic> mRNA levels in <italic>Zmat3</italic>-KO MEFs (<xref rid="fig2" ref-type="fig">Figure 2F</xref>).</p>
<p>In the context of human CRC, analysis of the TCGA colorectal adenocarcinoma (COAD) cohort revealed that <italic>HKDC1</italic> mRNA levels were significantly higher in tumors as compared to normal tissues (<xref rid="fig2" ref-type="fig">Figure 2G</xref>). Further analysis of the TCGA COAD data showed that, as compared to p53 wild-type tumors, mutant p53 tumors exhibited significantly higher <italic>HKDC1</italic> mRNA levels (Figure 2-figure supplement 1H). As expected for the p53-induced gene ZMAT3, and as shown previously in other cancer types<sup><xref ref-type="bibr" rid="c17">17</xref></sup>, <italic>ZMAT3</italic> mRNA levels were significantly lower in the mutant p53 tumors compared to p53 wild-type tumors (Figure 2-figure supplement 1I). Furthermore, RNA-seq from <italic>Trp53</italic> knockout MEFs from the same study<sup><xref ref-type="bibr" rid="c31">31</xref></sup> showed significant upregulation (∼8.6-fold) of <italic>Hkdc1</italic> mRNA, and down-regulation of <italic>Trp53</italic> and its target genes <italic>Zmat3</italic> and <italic>Cdkn1a</italic> (<italic>p21</italic>) (<xref rid="fig2" ref-type="fig">Figure 2H</xref>). Collectively, these data suggest that <italic>ZMAT3</italic> and <italic>HKDC1</italic> mRNA expression levels are negatively correlated within the p53 pathway and inhibition of <italic>HKDC1</italic> expression by ZMAT3 and p53 is conserved between humans and mice.</p>
</sec>
<sec id="s2c">
<title>ZMAT3 inhibits mitochondrial respiration by downregulating HKDC1</title>
<p>Previous studies suggest that HKDC1 plays a crucial role in regulating glucose metabolism and proliferation in various cell types<sup><xref ref-type="bibr" rid="c27">27</xref>,<xref ref-type="bibr" rid="c28">28</xref></sup>. To determine whether ZMAT3 regulates glucose metabolism and/or proliferation by regulating <italic>HKDC1</italic> expression, we performed glucose metabolic assays. Since HKDC1 is a hexokinase that catalyzes the phosphorylation of glucose to glucose 6-phosphate upon entry into cells, we measured changes in hexokinase activity upon ZMAT3 depletion. We incubated the cells with the non-catabolic glucose analog 2-deoxy glucose (2-DG) for a short period of time and quantified the conversion of 2-DG to 2-DG6P using a luminescence-based assay. We observed a significant increase in relative 2-DG6P levels in <italic>ZMAT3</italic>-KO cells compared to WT cells and interestingly, this increase was reversed upon <italic>HKDC1</italic> knockdown (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). Furthermore, siRNA-mediated knockdown of <italic>ZMAT3</italic> in SW1222 and HEPG2 also showed a similar increase in hexokinase activity that was reversed upon simultaneous knockdown of <italic>ZMAT3</italic> and <italic>HKDC1</italic>, suggesting that ZMAT3 inhibits glucose uptake, and this effect is HKDC1-dependent (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). We next determined if increased hexokinase activity upon <italic>ZMAT3</italic> knockdown leads to increased glycolysis in cells. To do this, we performed Seahorse assays to measure extracellular acidification rate and calculated the glycolysis proton efflux. It should be noted that the proton efflux rate measured with Seahorse is reflecting the lactate production from glycolysis more than the pyruvate end point of glycolysis that fueled the mitochondria. Thus, we also measured mitochondria activity. Knockdown of <italic>ZMAT3</italic> or <italic>HKDC1</italic> by siRNAs resulted in modest, but not significant increase in basal glycolysis (<xref rid="fig3" ref-type="fig">Figure 3B</xref>).</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title>ZMAT3 inhibits mitochondrial respiration via HKDC1.</title>
<p><bold>(A)</bold> Glucose uptake was measured using a 2-deoxyglucose analog and a luminescence-based enzymatic assay in <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells in presence or absence of <italic>HKDC1</italic>. For SW122 and HEPG2 cells, relative glucose uptake was measured following siRNA-mediated knockdown of <italic>HKDC1</italic> and/or <italic>ZMAT3</italic>. <bold>(B, C)</bold> Metabolic flux assays were performed to measure basal glycolysis rate and basal mitochondrial respiration rate in HCT116 cells after <italic>ZMAT3</italic> and/or <italic>HKDC1</italic> knockdown. (<bold>D, E</bold>) Incucyte live-cell proliferation assays and CCK8-based cell proliferation assays in <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells in the presence or absence of siRNA-mediated <italic>HKDC1</italic> knockdown. Data represent mean ± SEM of three independent experiments. ∗p &lt; 0.05, (∗∗) p &lt; 0.01, (∗∗∗) p&lt;0.001.</p></caption>
<graphic xlink:href="653341v2_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Recent studies suggest that HKDC1 plays a significant role in regulating mitochondrial respiration, and depletion of <italic>HKDC1</italic> results in mitochondrial dysfunction and senescence<sup><xref ref-type="bibr" rid="c26">26</xref>,<xref ref-type="bibr" rid="c27">27</xref></sup>. We therefore examined whether ZMAT3 regulates basal mitochondrial respiration by inhibiting <italic>HKDC1</italic> expression. To this end, we performed Seahorse assays to measure the oxygen consumption rate (OCR) following knockdown of <italic>HKDC1</italic> and/or <italic>ZMAT3</italic>. Interestingly, <italic>ZMAT3</italic> knockdown resulted in a significant increase in basal mitochondrial respiration, and simultaneous <italic>ZMAT3</italic> and <italic>HKDC1</italic> knockdown rescued this effect (<xref rid="fig3" ref-type="fig">Figure 3C</xref>), without altering oxygen consumption from non-mitochondrial respiration (Figure 3-figure supplement 1). These data indicate that <italic>ZMAT3</italic> regulates mitochondrial respiration without significantly affecting glycolysis. It is possible that mitochondria in <italic>ZMAT3</italic>-KO cells oxidize substrates other than those derived from glycolysis. Further studies will be required to determine these mechanisms in detail.</p>
<p>Because these phenotypes can be associated with proliferation, we next asked whether HKDC1 regulates proliferation and whether it is an effector of ZMAT3. Live cell proliferation assays and cell counting kit-8 (CCK-8) cell viability assays showed that knocking down <italic>HKDC1</italic> in <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO cells resulted in decreased proliferation but the effect of <italic>HKDC1</italic> knockdown was more pronounced in <italic>ZMAT3</italic>-KO cells (<xref rid="fig3" ref-type="fig">Figure 3D</xref> and <xref rid="fig3" ref-type="fig">E</xref>). This observation was unexpected, given that HKDC1 acts downstream of ZMAT3. One possible explanation is that elevated <italic>HKDC1</italic> expression in <italic>ZMAT3</italic>-KO cells increases their reliance on HKDC1 for sustaining proliferation, and that HKDC1 may also participate in additional pathways in <italic>ZMAT3</italic>-KO cells. Consequently, transient knockdown of <italic>HKDC1</italic> in <italic>ZMAT3</italic>-KO cells would have a more pronounced effect on proliferation due to their increased dependency on HKDC1 activity. In contrast, <italic>ZMAT3</italic>-WT cells which express lower levels of <italic>HKDC1</italic> are less dependent on its function and therefore less sensitive to its depletion.</p>
</sec>
<sec id="s2d">
<title>The p53/ZMAT3 axis inhibits HKDC1 expression</title>
<p>Because <italic>ZMAT3</italic> transcription is activated by p53, we next examined whether the p53 pathway inhibits <italic>HKDC1</italic> expression. To this end, we performed RNA-seq on HCT116 cells transfected with siCTRL or s<italic>ip53</italic> (SMARTpool of four siRNAs). Interestingly, <italic>HKDC1</italic> mRNA was significantly up-regulated (∼2.2-fold) upon <italic>p53</italic> knockdown (<xref rid="fig4" ref-type="fig">Figure 4A</xref>, <xref rid="fig4" ref-type="fig">4B</xref> and Table S4). As expected, <italic>p53</italic> knockdown led to strong downregulation of mRNAs encoding <italic>p53</italic> and its target genes <italic>p21</italic> and <italic>ZMAT3</italic> (<xref rid="fig4" ref-type="fig">Figure 4A</xref> and <xref rid="fig4" ref-type="fig">4B</xref>). We validated the observed up-regulation of <italic>HKDC1</italic> upon <italic>p53</italic> knockdown by RT-qPCR and immunoblotting (<xref rid="fig4" ref-type="fig">Figure 4C</xref> and <xref rid="fig4" ref-type="fig">4D</xref>). In these experiments, mRNA and/or protein levels of p53, p21 and ZMAT3 were markedly decreased upon <italic>p53</italic> knockdown (<xref rid="fig4" ref-type="fig">Figure 4C</xref> and <xref rid="fig4" ref-type="fig">4D</xref>). At the transcriptome-wide level, ∼2850 genes were differentially expressed (p&lt;0.05) upon <italic>p53</italic> knockdown (Table S4 and Figure 4-figure supplement 1A). Intersection of these differentially expressed genes (p&lt;0.05) with those regulated by <italic>ZMAT3</italic> identified 351 genes commonly upregulated and 425 genes commonly downregulated genes (Figure 4- figure supplement 1B and C). GSEA revealed enrichment of glycolysis and the p53 pathway, for the genes upregulated or downregulated following knockdown of <italic>p53</italic> or in <italic>ZMAT3</italic>-KO, respectively (Figure 4- figure supplement 1D and E).</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>p53 negatively regulates <italic>HKDC1</italic> expression in a ZMAT3-dependent manner.</title>
<p><bold>(A)</bold> IGV snapshots from RNA-seq data following knockdown of <italic>p53</italic> using <italic>p53</italic> siRNAs in HCT116 cells. <bold>(B)</bold> Fold change for <italic>p53, p21, ZMAT3</italic>, and <italic>HKDC1</italic> mRNA levels from RNA-seq of HCT116 cells transfected with siCTRL and sip53. <bold>(C, D)</bold> HCT116 cells were transfected with siCTRL or <italic>p53</italic> siRNAs for 48 h. <italic>ZMAT3, p53</italic> and <italic>HKDC1</italic> mRNA or protein were measured by RT-qPCR <bold>(C)</bold> or immunoblotting of whole-cell lysates <bold>(D)</bold>. <italic>GAPDH</italic> served as the housekeeping gene control. <bold>(E)</bold> Fold change in <italic>ZMAT3</italic>, <italic>p21</italic>, <italic>HKDC1</italic> and <italic>p53</italic> mRNA levels from RNA-seq of HCT116 cells treated with DMSO or Nutlin for 6 h. “ns” denotes not significant. <bold>(F)</bold> Immunoblotting of whole-cell lysates from <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 with or without Nutlin treatment for 24 h. GAPDH served as the loading control. (<bold>G, H</bold>) Doxycycline (Doxy)- inducible ZMAT3-FLAG-HA HCT116 cells were treated with 2 µg/mL doxycycline for 48 h. <italic>ZMAT3</italic> mRNA and ZMAT3-FLAG-HA protein induction were measured by RT-qPCR <bold>(G)</bold> and immunoblotting using an anti-HA antibody <bold>(H)</bold>. <italic>GAPDH</italic> served as the housekeeping control. <bold>(I, J)</bold> Doxycycline-inducible ZMAT3-FLAG-HA HCT116 cells were transfected with CTRL siRNA or <italic>p53</italic> siRNAs for 48 h, followed by 48 h of doxycycline treatment. <italic>ZMAT3, p53</italic>, and <italic>HKDC1</italic> mRNA and protein levels were measured by RT-qPCR <bold>(I)</bold> or immunoblotting from whole-cell lysates <bold>(J)</bold>. <italic>GAPDH</italic> served as the housekeeping gene control. ∗p &lt; 0.05, ∗∗p &lt; 0.01, ∗∗∗p &lt; 0.001, ∗∗∗∗p &lt; 0.0001</p></caption>
<graphic xlink:href="653341v2_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Since <italic>p53</italic> knockdown resulted in increased <italic>HKDC1</italic> expression, we next asked whether increasing p53 expression would lead to downregulation of <italic>HKDC1</italic>. Indeed, analysis of our RNA-seq data revealed ∼40% reduction in <italic>HKDC1</italic> mRNA levels following Nutlin treatment of siCTRL-transfected HCT116 cells (<xref rid="fig4" ref-type="fig">Figure 4E</xref> and Table S3). As expected for a direct p53 target gene, p53 activation by Nutlin led to upregulation of <italic>ZMAT3</italic> and <italic>p21</italic> mRNAs by ∼2.5- and ∼6-fold, respectively, while <italic>p53</italic> mRNA remain unchanged as Nutlin specifically stabilizes p53 protein levels (<xref rid="fig4" ref-type="fig">Figure 4E</xref>). At the protein level, p53 activation by Nutlin decreased HKDC1 levels and increased ZMAT3 and p21 levels in <italic>ZMAT3</italic>-WT cells (<xref rid="fig4" ref-type="fig">Figure 4F</xref>). In <italic>ZMAT3</italic>-KO cells, basal HKDC1 levels were modestly higher, and Nutlin treatment resulted in a slight decrease (<xref rid="fig4" ref-type="fig">Figure 4F</xref>). To further examine this regulation, we generated doxycycline-inducible ZMAT3-FLAG-HA expressing HCT116 cells to overexpress ZMAT3. Following 48 h of doxycycline treatment ZMAT3-FLAG-HA induction was confirmed by RT-qPCR and immunoblotting (<xref rid="fig4" ref-type="fig">Figure 4G</xref> and <xref rid="fig4" ref-type="fig">4H</xref>). Furthermore, knockdown of <italic>p53</italic> in these cells resulted in a significant increase in both <italic>HKDC1</italic> mRNA and protein levels under untreated conditions. Importantly, upon inducing ZMAT3 levels using doxycycline, the upregulation of <italic>HKDC1</italic> mRNA and protein associated with <italic>p53</italic> knockdown was no longer observed (<xref rid="fig4" ref-type="fig">Figure 4I</xref> and <xref rid="fig4" ref-type="fig">4J</xref>). Collectively these data demonstrate that the p53/ZMAT3 axis plays a critical role in the regulating <italic>HKDC1</italic> expression, with ZMAT3 acting downstream of p53 to inhibit <italic>HKDC1</italic> expression.</p>
</sec>
<sec id="s2e">
<title>ZMAT3 inhibits <italic>HKDC1</italic> transcription by interacting with the transcriptional activator JUN</title>
<p>ZMAT3 is an RNA-binding protein that regulates alternative splicing. We therefore hypothesized that ZMAT3 directly binds to the <italic>HKDC1</italic> pre-mRNA and regulates its splicing. However, in our previously published ZMAT3 PAR-CLIP<sup><xref ref-type="bibr" rid="c20">20</xref></sup>, we did not detect binding of ZMAT3 to <italic>HKDC1</italic> pre-mRNA (data not shown). Furthermore, in RNA immunoprecipitation (RIP) assays performed in doxycycline-inducible ZMAT3-FLAG-HA HCT116 cells, we did not observe significant enrichment of <italic>HKDC1</italic> mRNA in the anti-FLAG RNA-IPs (Figure 5-figure supplement 1A). These data suggest that ZMAT3 does not bind to <italic>HKDC1</italic> mRNA or pre-mRNA. Moreover, we analyzed changes in <italic>HKDC1</italic> pre-mRNA splicing using rMATS in HCT116 cells by reanalyzing our previously published RNA-seq data from siCTRL- and siZMAT3-transfected cells<sup><xref ref-type="bibr" rid="c20">20</xref></sup>. We focused on splicing events with an adj.p&lt;0.05 and a ΔPSI &gt; |0.1| (representing at least a 10% change in splicing). The splicing analysis did not reveal any significant alterations in <italic>HKDC1</italic> pre-mRNA splicing upon <italic>ZMAT3</italic> knockdown, suggesting that the observed increase in <italic>HKDC1</italic> mRNA is not at the level of splicing (data not shown).</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5.</label>
<caption><title>ZMAT3 inhibits <italic>HKDC1</italic> transcription by interacting with the transcription factor JUN.</title>
<p><bold>(A</bold>) Schematic of the workflow used to identify ZMAT3-FLAG-HA interacting proteins by IP-mass spectrometry in HCT116 cells expressing doxycycline-induced ZMAT3-FLAG-HA. <bold>(B)</bold> Volcano plot showing significantly enriched proteins (shown in red) identified by anti-FLAG IPs followed by mass spectrometry in the presence and absence of doxycycline in ZMAT3-FLAG-HA HCT116 cells. The vertical dotted line denotes a &gt;10-fold enrichment cutoff. JUN was strongly enriched in the ZMAT3-FLAG IPs. (<bold>C</bold>) IGV snapshot showing JUN, POLR2A, H3K27Ac and H3K4Me3 peaks at the <italic>HKDC1</italic> locus from ChIP-seq data from the ENCODE cell line datasets (accessions from top to bottom: ENCSR000FAH, ENCSR000EDG, ENCSR000EEK, ENCSR000EUU, ENCSR661KMA and ENCSR333OPW). The JUN binding motif (TGASTCA) is shown in blue (positive strand) and in red (negative strand). (<bold>D</bold>) IP followed by immunoblotting using anti-FLAG beads and whole-cell lysates from untreated (no doxy) or doxy-treated ZMAT3-FLAG-HA HCT116 cells. Ten percent of cell lysate was used as input. GAPDH served as the loading control. <bold>(E, F)</bold> <italic>ZMAT3</italic>- WT and <italic>ZMAT3</italic>-KO HCT116 cells were transfected with CTRL siRNA or JUN siRNAs for 48 h, followed by RT-qPCR <bold>(E)</bold> or immunoblotting of whole-cell lysates <bold>(F)</bold>. GAPDH served as the housekeeping control. <bold>(G</bold>) JUN ChIP-qPCR was performed in biological triplicates from <italic>ZMAT3</italic>-WT and <italic>ZMAT3-</italic>KO HCT116 cells to determine the enrichment of JUN at <italic>HKDC1</italic> intron 1. <bold>(H)</bold> Luciferase assays were performed in biological triplicates following <italic>JUN</italic> and/or <italic>ZMAT3</italic> knockdown, and pGL4 or pGL4 construct containing the <italic>HKDC1</italic> intron 1 region. ∗p &lt; 0.05, ∗∗p &lt; 0.01</p></caption>
<graphic xlink:href="653341v2_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Because ZMAT3 has three C2H2-zinc-finger motifs, it has the potential to bind DNA (Figure 5-figure supplement 1B)<sup><xref ref-type="bibr" rid="c32">32</xref>–<xref ref-type="bibr" rid="c34">34</xref></sup>. A recent study also reported that ZMAT3 and other zinc finger proteins function as dual DNA-RNA binding proteins (DRBPs)<sup><xref ref-type="bibr" rid="c33">33</xref></sup>. To determine whether ZMAT3 binds DNA and regulates <italic>HKDC1</italic> transcription directly, we performed ZMAT3-FLAG-HA CUT&amp;RUN-seq and ChIP-seq in three biological replicates using anti-HA, anti-FLAG, or anti-ZMAT3 antibodies. However, we did not detect reproducible ZMAT3 binding at the <italic>HKDC1</italic> locus or at other genomic regions in HCT116 cells (data not shown).</p>
<p>We therefore hypothesized that ZMAT3 inhibits HKDC1 expression by interacting with a specific transcription factor. To identify proteins that interact with ZMAT3, we performed IPs using an anti-FLAG antibody followed by mass spectrometry on whole-cell lysates from untreated or doxycycline-treated ZMAT3-FLAG-HA HCT116 cells (<xref rid="fig5" ref-type="fig">Figure 5A</xref> and Figure 5-figure supplement 1C). After filtering out common contaminants (&lt;10% in CRAPome), this unbiased approach identified 21 ZMAT3-interacting proteins (<xref rid="fig5" ref-type="fig">Figure 5B</xref> and Table S5). As expected, ZMAT3 was the most strongly enriched protein (∼36,000-fold). Of note, due to the low abundance of ZMAT3 in one of the control samples, the p-value for ZMAT3 enrichment was not highly significant (p=0.09) (Table S5).</p>
<p>Interestingly, the transcription factor JUN (c-Jun) was strongly enriched in the ZMAT3-FLAG pulldowns (∼8,500-fold). JUN is a proto-oncogene previously implicated in glucose metabolism<sup><xref ref-type="bibr" rid="c35">35</xref>,<xref ref-type="bibr" rid="c36">36</xref></sup> and p53 function<sup><xref ref-type="bibr" rid="c37">37</xref>,<xref ref-type="bibr" rid="c38">38</xref></sup>. To further explore this potential regulatory link, we analyzed publicly available JUN ChIP-seq data from multiple ENCODE cell lines, focusing on JUN binding at the HKDC1 locus. Notably, in three cell lines, we found a JUN ChIP-seq peak containing the consensus JUN-binding motif within <italic>HKDC1</italic> intron 1. This peak coincided with ChIP-seq peaks for POLR2A, H3K27Ac and H3K4Me3 in HCT116 cells (<xref rid="fig5" ref-type="fig">Figure 5C</xref>). We next validated the interaction between ZMAT3 and JUN by performing anti-FLAG IPs followed by immunoblotting on whole-cell lysates from untreated or doxycycline-treated ZMAT3-FLAG-HA HCT116 cells (<xref rid="fig5" ref-type="fig">Figure 5D</xref>). Treatment with DNase or RNase abolished the interaction between ZMAT3 and JUN, indicating that nucleic acids mediate their association (Figure 5-figure supplement 1D).</p>
<p>Importantly, <italic>JUN</italic> knockdown resulted in decreased <italic>HKDC1</italic> mRNA levels in <italic>ZMAT3</italic>-WT cells and rescued the elevated <italic>HKDC1</italic> mRNA and protein levels observed in <italic>ZMAT3</italic>-KO cells (<xref rid="fig5" ref-type="fig">Figure 5E</xref> and <xref rid="fig5" ref-type="fig">F</xref>). To determine whether ZMAT3 inhibits JUN binding to the <italic>HKDC1</italic> locus, we performed ChIP-qPCR for JUN in <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO cells. JUN showed significant enrichment at the <italic>HKDC1</italic> intron 1 region compared to the IgG control in <italic>ZMAT3</italic>-WT cells, and this enrichment was further increased in <italic>ZMAT3</italic>-KO cells, indicating that ZMAT3 inhibits JUN binding to the <italic>HKDC1</italic> intron 1 DNA. We next cloned a ∼700 bp DNA fragment encompassing the JUN and POLR2A binding peaks within <italic>HKDC1</italic> intron 1 into the pGL4 basic luciferase reporter vector, hereafter referred to as pGL4-HKDC1-intron 1. Knockdown of <italic>JUN</italic> in HCT116 cells significantly decreased luciferase activity of the <italic>HKDC1</italic> reporter (<xref rid="fig5" ref-type="fig">Figure 5H</xref>). Conversely, <italic>ZMAT3</italic> knockdown led to a marked increase in luciferase activity, which was rescued by simultaneous knockdown of <italic>ZMAT3</italic> and <italic>JUN</italic> (<xref rid="fig5" ref-type="fig">Figure 5H</xref>).</p>
<p>Next, to identify additional c-JUN targets potentially regulated by ZMAT3, we intersected the genes upregulated upon ZMAT3 knockout (from our RNA-seq data) with the ChIP-Atlas dataset for human c-JUN and cross-referenced these with c-JUN peaks from three ENCODE cell lines. From this analysis, we selected for further analysis the top 4 candidate genes - <italic>LAMA2</italic>, <italic>VSNL1</italic>, <italic>SAMD3</italic>, and <italic>IL6R</italic> (Figure 5-figure supplement 2A-D). Like <italic>HKDC1</italic>, these genes were upregulated in <italic>ZMAT3</italic>-KO cells, and this upregulation was abolished upon siRNA-mediated <italic>JUN</italic> knockdown in <italic>ZMAT3</italic>-KO cells (Figure 5-figure supplement 2E). Moreover, by ChIP-qPCR we observed increased JUN binding to the JUN peak for these genes in <italic>ZMAT3</italic>-KO cells as compared to the <italic>ZMAT3</italic>-WT (Figure 5-figure supplement 2F). These data suggest that the ZMAT3/JUN axis negatively regulates <italic>HKDC1</italic> expression and additional c-JUN target genes.</p>
<p>Collectively, these data suggest that <italic>ZMAT3</italic> plays a crucial role in regulating mitochondrial respiration and cell proliferation by suppressing <italic>HKDC1</italic> transcription. We propose a model in which, in <italic>ZMAT3</italic>-WT cells p53 drives <italic>ZMAT3</italic> transcription, and ZMAT3 protein binds to JUN, thereby inhibiting JUN binding to the <italic>HKDC1</italic> locus and repressing <italic>HKDC1</italic> transcription. This repression maintains controlled mitochondrial respiration and proliferation. In the absence of <italic>ZMAT3</italic>, increased JUN binding at the <italic>HKDC1</italic> locus leads to elevated <italic>HKDC1</italic> expression, enhanced mitochondrial respiration, and increased proliferation (<xref rid="fig6" ref-type="fig">Figure 6</xref>).</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6.</label>
<caption><title>Model of ZMAT3-mediated regulation of <italic>HKDC1</italic> expression and mitochondrial respiration.</title>
<p>In <italic>ZMAT3</italic>-WT cells, p53 activates <italic>ZMAT3</italic> transcription, leading to ZMAT3 protein binding to the transcription factor JUN. This interaction inhibits JUN binding to the <italic>HKDC1</italic> locus, resulting in low <italic>HKDC1</italic> expression and controlled mitochondrial respiration and cell proliferation. In <italic>ZMAT3</italic>-KO cells, JUN actively binds to the <italic>HKDC1</italic> locus and upregulates its expression, leading to increased mitochondrial respiration and enhanced cell proliferation.</p></caption>
<graphic xlink:href="653341v2_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Recent studies suggest that ZMAT3 significantly contributes to the tumor suppressive effects of p53<sup><xref ref-type="bibr" rid="c17">17</xref>,<xref ref-type="bibr" rid="c18">18</xref></sup>. At the molecular level, ZMAT3 typically functions as an RNA-binding protein that acts as a key splicing factor and also regulate mRNA stability<sup><xref ref-type="bibr" rid="c17">17</xref>,<xref ref-type="bibr" rid="c20">20</xref></sup>. Here, we unexpectedly found that transcription of <italic>HKDC1</italic>, the gene that is most strongly upregulated at the protein level in <italic>ZMAT3</italic>-deficient cells, is indirectly repressed by ZMAT3 through its interaction with the transcription factor JUN, thereby inhibiting JUN’s binding to the <italic>HKDC1</italic> locus. Consistent with the established role of HKDC1 in glucose metabolism and mitochondrial respiration, ZMAT3 depletion led to increased mitochondrial respiration, a phenotype that was rescued by simultaneous knockdown of <italic>ZMAT3</italic> and <italic>HKDC1</italic>. These findings suggest that <italic>HKDC1</italic> is a key downstream effector of ZMAT3 in regulating cellular metabolism.</p>
<p>ZMAT3 has been known as a p53 target gene for more than two decades<sup><xref ref-type="bibr" rid="c39">39</xref>,<xref ref-type="bibr" rid="c40">40</xref></sup>, yet its physiological functions and role in tumor suppression are only beginning to be understood. ZMAT3 belongs to the zinc finger family of proteins that play crucial roles in regulating gene expression through specific recognition of DNA sequences<sup><xref ref-type="bibr" rid="c41">41</xref></sup>. Although primarily known for their involvement in transcription, these proteins have also been found to interact with RNA and proteins<sup><xref ref-type="bibr" rid="c42">42</xref>,<xref ref-type="bibr" rid="c43">43</xref></sup>. Among them, ZMAT3 is a member of the ZMAT domain-containing family that has three zinc fingers of C2H2-type zinc fingers motif <sup><xref ref-type="bibr" rid="c44">44</xref>,<xref ref-type="bibr" rid="c45">45</xref></sup>. These domains play crucial roles in gene regulation by specifically binding to target molecules such as DNA and RNA. A recent study<sup><xref ref-type="bibr" rid="c33">33</xref></sup> revealed ZMAT3 as a DRBP (DNA- and RNA-binding protein), but in our hands using CUT&amp;RUN-seq and ChIP-seq, we did not observe specific binding of ZMAT3-FLAG-HA or endogenous ZMAT3 to DNA (data not shown). In contrast, parallel, CUT&amp;RUN-seq and ChIP-seq assays for p53 performed exceedingly well (data not shown), confirming that the lack of ZMAT3 signal was not due to a technical limitation. It is possible that ZMAT3’s interaction with DNA is cell type-specific or occurs under specific conditions, such as following DNA damage, but this required further investigation.</p>
<p>Our findings that ZMAT3 interacts with and inhibits binding of JUN to the <italic>HKDC1</italic> locus provides mechanistic insights on how ZMAT3, without directly interacting with DNA regulates <italic>HKDC1</italic> transcription. JUN is a protooncogene that plays a crucial role in both normal physiological processes and tumorigenesis by regulating cell proliferation, differentiation, senescence and metastasis<sup><xref ref-type="bibr" rid="c46">46</xref>–<xref ref-type="bibr" rid="c49">49</xref></sup>. It functions as transcription factor and a key component of AP-1 complex and promotes RNA polymerase II mediated transcription of target genes<sup><xref ref-type="bibr" rid="c50">50</xref></sup>. Our data indicates that the ZMAT3–JUN interaction requires both DNA and RNA, indicating ZMAT3 and JUN form RNA-dependent, chromatin-associated complex. Although not investigated in our study, this aligns with emerging views that RBPs can function as chromatin-associated cofactors in transcription<sup><xref ref-type="bibr" rid="c51">51</xref>–<xref ref-type="bibr" rid="c54">54</xref></sup>. For instance, functional interplay between transcription factor YY1 and the RNA binding protein RBM25 co-regulates a broad set of genes, where RBM25 appears to engage promoters first and then recruit YY1, with RNA proposed to guide target recognition<sup><xref ref-type="bibr" rid="c51">51</xref></sup>. Future investigations are needed to determine the domains of JUN that interact with ZMAT3, in case there is direct interaction between these proteins, and what RNAs shapes the ZMAT3 and JUN interaction within genome. Although we did not detect chromatin binding of ZMAT3 with current reagents, improved ChIP-grade antibodies or endogenous epitope tagging (for ChIP-seq and CUT&amp;RUN-seq) might clarify whether ZMAT3 occupies chromatin at physiological levels and how it modulates JUN binding to its target genes.</p>
<p>Because ZMAT3 regulates alternative splicing which can lead to changes in protein levels without altering mRNA levels, in this study we integrated global quantitative proteomics with RNA-seq data from <italic>ZMAT3</italic>-WT and isogenic <italic>ZMAT3</italic>-KO CRC cells. Furthermore, we integrated these data with RNA-seq from HCT116 cells upon <italic>ZMAT3</italic> or <italic>p53</italic> knockdown using siRNAs, to make sure that the findings from the isogenic cell lines were not restricted to a single KO clone and to determine the role of the p53/ZMAT3 axis in regulating these genes. This approach identified HKDC1 as the most strongly upregulated protein upon ZMAT3 depletion. HKDC1 is emerging as an important regulator of tumor progression and is frequently upregulated in several cancers including CRC<sup><xref ref-type="bibr" rid="c55">55</xref>–<xref ref-type="bibr" rid="c57">57</xref></sup>. Besides its hexokinase activity, HKDC1 interacts with the mitochondrial membrane and plays an essential role in mitochondrial function<sup><xref ref-type="bibr" rid="c26">26</xref>,<xref ref-type="bibr" rid="c27">27</xref></sup>. We further demonstrated that ZMAT3 suppresses glucose uptake and basal mitochondrial respiration by inhibiting <italic>HKDC1</italic> expression leading to suppression of cell proliferation in CRC cells.</p>
<p>Our data also demonstrates that p53 negatively regulates <italic>HKDC1</italic> expression and this effect is ZMAT3-dependent, suggesting that the p53/ZMAT3/HKDC1 axis is an important component of the p53 network, specifically in the context of mitochondrial respiration and proliferation. The ability of p53 to induce cell cycle arrest and programmed cell death is important for tumor suppressor<sup><xref ref-type="bibr" rid="c58">58</xref></sup>. However, p53 has several other functions that recent data strongly implicate in tumor suppression, particularly regarding the control of metabolism such as glycolysis, mitochondrial respiration, and ferroptosis<sup><xref ref-type="bibr" rid="c59">59</xref>,<xref ref-type="bibr" rid="c60">60</xref></sup>. Metabolic reprogramming is a hallmark of cancer cells, which plays a pivotal role in cancer progression by providing energy and a wide variety of substrates for biosynthesis to support the rapid proliferation and survival of cancer cells<sup><xref ref-type="bibr" rid="c61">61</xref>–<xref ref-type="bibr" rid="c63">63</xref></sup>. p53 has been reported to play an important role in suppressing tumor development by regulating the expression and function of metabolic genes, directly <italic>(GLUT1</italic><sup><xref ref-type="bibr" rid="c64">64</xref></sup>, <italic>GLUT4</italic><sup><xref ref-type="bibr" rid="c64">64</xref></sup>, <italic>PFKFB3</italic><sup><xref ref-type="bibr" rid="c65">65</xref></sup> and <italic>PFKFB4</italic><sup><xref ref-type="bibr" rid="c66">66</xref></sup>) or indirectly (<italic>HK2</italic><sup><xref ref-type="bibr" rid="c67">67</xref></sup><italic>, HIF1</italic> <sup><xref ref-type="bibr" rid="c68">68</xref></sup> and <italic>G6PD</italic><sup><xref ref-type="bibr" rid="c69">69</xref></sup>). Our data uncovers HKDC1 as an indirect p53 target gene that is negatively regulated via ZMAT3. Collectively, our findings provide key insights into the diverse functions of ZMAT3 and their involvement in gene regulation in the p53 pathway.</p>
</sec>
<sec id="s4">
<title>Materials and Methods</title>
<sec id="s4a">
<title>Cell lines</title>
<p>HCEC-1CT, HepG2, HCT116 and HEK293T cells were purchased from the American Type Culture Collection (ATCC), and SW1222 cells were purchased from Cellosaurus. Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher Scientific, Catalog no. 11995065) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Catalog no. 10082147) and 100 U/mL of penicillin and 0.1 mg/mL of streptomycin (Thermo Fisher Scientific, Catalog no. 15070063). Cultures were incubated at 37 °C in a humidified atmosphere containing 5% CO<sub>2</sub>. All cell lines were regularly tested for mycoplasma using the Venor™ GeM Mycoplasma Detection Kit (Millipore Sigma, Catalog no. MP0025-1KT).</p>
</sec>
<sec id="s4b">
<title>Targeted deletion of ZMAT3 using CRISPR/Cas9</title>
<p>To generate <italic>ZMAT3</italic>-KO clones, we employed the PiggyBac CRISPR/Cas9 system developed from the Zhang lab<sup><xref ref-type="bibr" rid="c70">70</xref></sup>. Two sgRNAs flanking the p53RE within <italic>ZMAT3</italic> intron 2 were designed and individually cloned in pENTR221 vector. These constructs were electroporated into 1×10<sup>6</sup> parental HCT116 cells using the Amaxa Cell Line Nucleofector Kit (Lonza, Catalog no. VCA-1005), together with pT3.5-FLAG-Cas9, pCDNA-pB7, and pBSB-CG-LUC-GFP-(puro)(cre+) vectors. After two days, cells were treated with 2 µg/mL puromycin (Thermo Fisher Scientific, Catalog no. A1113803) for three days. Following puromycin selection, single cells were then seeded into 96-well plates to isolate <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO clones. Clones were expanded for three weeks and transferred to 24-well plates. Total RNA was isolated from each well, and ZMAT3 expression was measured by RT-qPCR and normalized to <italic>GAPDH</italic>. Genomic DNA was extracted from individual clones showing strong reduction of ZMAT3 expression, and the genomic region flanking the p53RE of ZMAT3 was PCR-amplified and verified by Sanger sequencing.</p>
</sec>
<sec id="s4c">
<title>Plasmids construction and lentivirus production</title>
<p>The pLVX-Puro-Tet-One vector from TaKaRa (631849) was used as a backbone to construct an expression construct encoding ZMAT3-3xFLAG-2xHA. The resulting plasmids were transformed into <italic>E. coli</italic> DH5α cells (Thermo Fisher Scientific, Catalog no. 18265017), and purified using the Monarch Plasmid Miniprep Kit (NEB, Catalog no. T1010L). Lentiviral particles were produced in 3×10<sup>5</sup> HEK293T cells after co-transfection of 1 µg of plasmid DNA and a third-generation lentiviral packaging system using Lipofectamine 2000 (Thermo Fisher Scientific Catalog no. 11668027). HCT116 cells were transduced at a multiplicity of infection (MOI) of ∼1 and, after 2 days, were selected with 2 μg/mL puromycin (Thermo Fisher Scientific, Catalog no. A1113803) for 1 week.</p>
<p>For luciferase assays, a 706 bp genomic region encompassing the JUN-binding peak within the <italic>HKDC1</italic> locus was cloned into the pGL4-Basic vector (Promega, Catalog no. E6651), generating the pGL4-HKDC1-intron 1 reporter. To do this, a gene fragment corresponding to chr10:69,222,339-69,223,043 (hg38) was synthesized by Twist Bioscience and included restriction sites for KpnI (NEB, Catalog no. R3142) and XhoI (NEB, Catalog no. R0146S) at 5′ and 3′ ends, respectively. Both the pGL4-Basic vector and insert DNA fragment were digested with these enzymes, purified using the Monarch DNA Gel Extraction Kit (NEB, Catalog no. T1020S) or QIAquick PCR purification kit (Qiagen, Catalog no. 28106), and ligated using T4 DNA ligase (NEB, Catalog no. M0202S) to generate the final pGL4-HKDC1-intron 1 luciferase reporter.</p>
</sec>
<sec id="s4d">
<title>siRNA transfections</title>
<p>Reverse transfections were performed using Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher Scientific Catalog, no.13778075) and Opti-MEM (Thermo Fisher Scientific, Catalog no. 31985062) in HCT116, HCEC-1CT, HepG2 and SW1222 cells according to the manufacturer’s protocol. The final concentration of siRNAs was 20 nM. For RT-qPCR and immunoblotting, two rounds of transfection were performed: the second transfection was performed 48 h after the first transfection and cells were harvested after 72 h. <italic>HKDC1</italic> siRNA transfections were conducted for only one round following the first transfection with siCTRL or si<italic>ZMAT3</italic>. Negative Control siRNA (Qiagen, Catalog no. 1027281) was used as control. The following SMARTpool siRNAs were used: si<italic>ZMAT3</italic> (Horizon Discovery, Catalog no. L-017382-00-0005), si<italic>JUN</italic> (Horizon Discovery, Catalog no. L-003268-00-0005) and si<italic>p53</italic> (Horizon Discovery, Catalog no. L-003329-00-0005). For metabolic assays, cells were transfected with siRNAs targeting more than one gene (e.g. si<italic>HKDC1</italic> and si<italic>ZMAT3</italic>) at 20 nM each. HCT116 cells expressing ZMAT3-FLAG-HA were transfected for 48 h, reseeded, and treated with 2 μg/mL doxycycline to induce ZMAT3-FLAG-HA expression.</p>
</sec>
<sec id="s4e">
<title>Luciferase assays</title>
<p>HCT116 cells were transfected with siRNAs for 48 h, and then 1×10<sup>5</sup> cells were reseeded in 24-well plates for luciferase assays. The following day, cells were co-transfected with 250 ng of pGL4 or pGL4-HKDC1-intron 1 and 25 ng of pRL-TK (Promega, Catalog no. E2231), together with 20 nM of either AllStars Negative Control siRNA, si<italic>JUN</italic> or si<italic>ZMAT3</italic>. Lipofectamine 2000 transfection reagent (Thermo Fisher Scientific, Catalog no. 11668027) was used for the co-transfections, according to the manufacturer’s protocol. After 2 days, firefly and Renilla luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega, Catalog no. E1910) on an EnSight Multimode plate reader (PerkinElmer). Firefly luminescence values were normalized to Renilla luminescence to account for transfection efficiency.</p>
</sec>
<sec id="s4f">
<title>RNA extraction and RT-qPCR</title>
<p>Cells were washed with 1 x DPBS (Thermo Fisher Scientific, Catalog no. 14190250) and total RNA was isolated using 500 μL of TRIzol Reagent (Thermo Fisher Scientific, Catalog no. 15596018). To prepare cDNA, 500 ng of total RNA was reverse-transcribed using the iScript™ Reverse Transcription Supermix (Bio-Rad, Catalog no. 1708841). Quantitative PCR (qPCR) was performed using 2.5 μL of diluted cDNA combined with 5 μL of 2x FastStart Universal SYBR Green Master (Rox) (Millipore Sigma, Catlog no. 4913914001) and 0.5 μM (final concentration) of each primer in a 10 μL total reaction volume on a StepOnePlus Real-Time PCR machine (Applied Biosystems). Fold change was calculated using the 2<sup>−ΔΔCt</sup> method, with <italic>GAPDH</italic> mRNA serving as housekeeping control.</p>
</sec>
<sec id="s4g">
<title>Immunoblotting</title>
<p>For immunoblotting, cells were lysed in 1 mL of RIPA buffer (Thermo Fisher Scientific, Catlog no. 89901). Lysates were sonicated three times for 5 seconds each at 50% amplitude using a VirTis VIRSONIC 100 sonicator and centrifuged at 16,000 x g for 10 min at 4 °C. The supernatant was collected, and protein concentration was determined using the Pierce<sup>TM</sup> BCA Protein Assay Kit (Thermo Fisher Scientific, Catalog no. 23225). For SDS-PAGE, 20 to 50 µg of total protein was loaded per lane and transferred to a PVDF membrane using a Bio-Rad semi-dry transfer apparatus. Membranes were blocked for 1 h with TBST (Tris-Buffered Saline: 19.98 mM Tris, 136 mM NaCl, and 0.05% Tween, pH 7.4) containing 5% skim milk and then incubated with the primary antibody overnight at 4 °C. The following primary antibodies were used: anti-FLAG (1:1000 dilution; Sigma, Catalog no. F1804), anti-p53 (DO-1) (1:1000 dilution; Santa Cruz Biotechnology, Catalog no. sc-126), anti-ZMAT3 (1:500 dilution; Santa Cruz Biotechnology, Catalog no. sc-398712), anti-JUN (1:1000 dilution; Cell Signaling, Catalog no. 9165S) and anti-HKDC1 (Proteintech, Catalog no: 25874-1-AP). Anti-GAPDH antibody (1:6000 dilution; Cell Signaling, 5174S) was used for loading control. After incubation with HRP-conjugated secondary antibody (1:5,000 dilution) for 1 h at room temperature, the immunoblot was developed using the ECL™ Prime Western Blotting Detection Reagent (Fisher Scientific, Catalog no. RPN2232). Band intensities were quantified using ImageJ software and normalized to GAPDH.</p>
</sec>
<sec id="s4h">
<title>Colony formation assays</title>
<p>One thousand <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells were seeded into 6-well plates. After 12 days, colonies were fixed with ice-cold methanol for 15 min and stained with 0.5% crystal violet (prepared in 10% methanol) for 15 min. Images were captured, and colony coverage area was quantified using ImageJ software.</p>
</sec>
<sec id="s4i">
<title>Incucyte Proliferation assays</title>
<p>For proliferation assays, 1,000 cells were seeded per well in a 96-well plate. Cells were incubated in an Incucyte® S3 Live-Cell Analysis System (Sartorius) and imaged every 6 h for 4 days. Images were analyzed using the manufacturer’s software to determine percent confluence over time.</p>
</sec>
<sec id="s4j">
<title>Cell viability assays</title>
<p>To determine cell viability, cells were incubated with Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan) for 4 h, and absorbance at 450 nm was measured using a Envision microplate reader (PerkinElmer).</p>
</sec>
<sec id="s4k">
<title>Glucose uptake assays</title>
<p>siCTRL, si<italic>ZMAT3</italic> and si<italic>HKDC1</italic> were transfected into HCT116, SW1222, and HepG2 cells seeded in poly-L-lysine–coated white 96-well plates with opaque bottoms (Costar) and incubated at 37 °C for 24 h. After the incubation, the growth medium was removed, and cells were washed twice with PBS to eliminate residual glucose. Glucose uptake was measured using the Glucose Uptake-Glo<sup>TM</sup> Assay Kit (Promega, Catalog no. J1341) according to the manufacturer’s instructions. Uptake was initiated by adding 1 mM 2-deoxyglucose and incubating for 10 min at 37 °C, after which luminescence was recorded using an Envision Multimode Plate Reader (PerkinElmer).</p>
</sec>
<sec id="s4l">
<title>Metabolic flux assays</title>
<p>First, HCT116 cells were reverse transfected with siCTRL or siZMAT3 for 48 h. After 48 hr, a second round of transfection was conducted in 24-well Seahorse plates (Agilent Technologies Inc, Catalog no. 100777-004,) at a concentration of 3×10<sup>4</sup> per 200 µl per well. After 48 h cells were washed twice with 500 mL of XF DMEM Medium, pH 7.4 (Agilent Technologies Inc, Catlog no. 103575-10) containing 1 mM pyruvate, 2 mM of glutamine and 10 mM of glucose (Agilent Technologies Inc, Catalog no. 103578-100, 103579-100, 103577-100). Eventually cells were incubated 45 min in a non-CO2 incubator prior to the assays. Meanwhile drugs from Mito Stress Test Kit (Agilent Technologies Inc, Catalog no. 103015-10) and Glycolytic Rate Assay Kit (Agilent Technologies Inc, Catalog no. 103344-100) were prepared in XF DMEM Medium, pH 7.4 containing 1mM pyruvate, 2 mM of glutamine and 10 mM of glucose. For the Mito Stress Test Kit the working drug solutions concentration were Oligomycin 1.5 µM, FCCP 1.0 µM and Rot/AA 0.5 µM. For the glycolytic Rate Assay Kit the working drug solutions concentration were Rot/AA 0.5 µM and 2-DG 50 mM. After the 45 min incubation, the plates were loaded into the Seahorse Analyzer and the commercial protocols for the drugs distribution were used. Immediately after the assays, media was removed from wells and cells frozen for later protein concentration measurement. Protein concentrations were measured with Pierce<sup>TM</sup> BCA Protein Assay kit (Thermo Fisher Scientific, Catalog no. 23225) and used to normalize Seahorse results.</p>
</sec>
<sec id="s4m">
<title>Gene set enrichment analysis</title>
<p>GSEA was performed using the MSigDB Hallmark gene sets from the Molecular Signature database (<ext-link ext-link-type="uri" xlink:href="https://www.gsea-msigdb.org/gsea/msigdb/human/annotate.jsp">https://www.gsea-msigdb.org/gsea/msigdb/human/annotate.jsp</ext-link>).</p>
</sec>
<sec id="s4n">
<title>Co-immunoprecipitation</title>
<p>ZMAT3-FLAG-HA coimmunoprecipitations were performed using anti-FLAG M2-coated magnetic beads (Sigma-Aldrich, Catalog no. M8823). Approximately 5 × 10<sup>7</sup> doxycycline treated or untreated HCT116 ZMAT3-FLAG-HA cells were lysed in IP lysis buffer (10 mM Tris/Cl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 0.5% NP40) supplemented with 1 mM PMSF and complete protease inhibitor cocktail (Roche). Lysates were incubated for 30 min at 4 °C with gentle mixing and clarified by centrifugation at 16,000 x g for 10 min at 4 °C. Equal amounts of clarified lysates were incubated with prewashed M2 beads overnight at 4 °C with constant rotation. Beads were magnetically separated from the unbound material and washed four times with IP wash buffer (10 mM Tris/Cl pH 7.5, 150 mM NaCl, 0.05% NP40, 0.5 mM EDTA). Bound proteins were eluted with FLAG elution buffer containing 125 µg/mL 3xFLAG peptide (Sigma-Aldrich, Catalog no. F4799). Equal volumes of eluates were boiled at 100 °C for 5 min in Laemmli sample buffer and then centrifuged at 16,000 x g for 5 min at room temperature. Total cell lysate was used as input, and proteins were detected by immunoblotting. For IP-mass spectrometry, bead-bound samples were processed directly after washing the beads, without the elution step.</p>
</sec>
<sec id="s4o">
<title>RNA-immunoprecipitation</title>
<p>ZMAT3-FLAG-HA RNA-immunoprecipitations were performed using anti-FLAG M2-coated magnetic beads (Sigma-Aldrich Catalog no. M8823), as described above for the co-IP assays. After the IPs, beads were magnetically separated from the unbound material and washed four times with IP Wash buffer. Bound RNAs were extracted directly from the beads using TRIzol<sup>TM</sup> Reagent (Thermo Fisher Scientific, Catalog no. 15596018) following the manufacturer’s protocol.</p>
</sec>
<sec id="s4p">
<title>ChIP-qPCR</title>
<p>ChIP-qPCR was performed using the ChIP-IT Express Kit (Active Motif, Catalog no. 53008) following the manufacturer’s instructions. Briefly, 5 × 10<sup>7</sup> <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells grown in 15-cm plates were cross-linked with 1% formaldehyde, scraped, lysed, and sheared. Chromatin fragment size was verified on a 1% agarose gel. Chromatin was immunoprecipitated overnight at 4 °C using 1 μg of anti-JUN antibody or IgG isotype control. The IP material was washed, eluted, and reverse crosslinked overnight at 65 °C. ChIP DNA was purified using the QIAquick PCR Purification Kit (Qiagen, Catalog no. 28104) and analyzed by qPCR. ChIP-qPCR primers were designed based on the genomic regions harboring JUN-binding peaks in <italic>HKDC1</italic>, <italic>LAMA2</italic>, <italic>VSNL1</italic>, <italic>SAMD3</italic>, <italic>IL6R</italic> (<xref rid="fig5" ref-type="fig">Figure 5C</xref> and Figure 5-figure supplement 2A-D).</p>
</sec>
<sec id="s4q">
<title>RNA-seq and analysis</title>
<p>RNA-seq was performed in biological triplicates from HCT116 <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO cells. Total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen, Catalog no. 74134) following the manufacturer’s instructions. Libraries were prepared using the Illumina Stranded mRNA Ligation Library Kit with 450 ng of total RNA as the input for mRNA capture using oligo(dT)- coated magnetic beads. The captured mRNA was fragmented and reverse-transcribed using random primes to synthesize first-strand cDNA, followed by second-strand synthesis. The resulting double-stranded cDNA was subjected to standard Illumina library preparation, including end repair, adapter ligation, and PCR amplification, to generate sequencing-ready libraries. The final purified libraries were quantified by qPCR prior to cluster generation and paired-end sequencing on NovaSeq 6000 platform using an SP 200-cycle kit. Demultiplexing and conversion of binary base call (BCL) files to FASTQ format were performed using Illumina bcl2fastq v2.20. Sequencing reads were trimmed to remove adapters and low-quality bases using Cutadapt (v1.18). Trimmed reads were aligned to the human reference genome (hg38) using the STAR aligner (v2.7.0f) with the two-pass alignment option and GENCODE annotation (v30). Gene and transcript quantification was performed using RSEM (v1.3.1) based on GENCODE annotation.</p>
</sec>
<sec id="s4r">
<title>Mass Spectrometry Sample Preparation</title>
<p>For total protein identification, cell pellets were suspended in 8 M urea buffer supplemented with protease and phosphatase inhibitors (Roche). All samples were transferred to 2-mL TissueLyser tubes containing 5-mm steel balls and kept on ice. Cells were lysed in a TissueLyser (Qiagen) for 2 × 2 min, with chilling at −20 °C for 2–3 min between cycles. Lysates were centrifuged at 12,500x g for 15 min at 4 °C, and supernatants were transferred to new tubes. Protein concentrations were measured using the BCA assay (Thermo Fisher Scientific). For downstream processing, 200 µg of protein from each sample was reduced with 10 mM DTT at 56 °C for 1 h and alkylated with 20 mM iodoacetamide at room temperature for 30 min in the dark. Following alkylation, samples were diluted four-fold with 50 mM triethylammonium bicarbonate (TEAB) to reduce the urea concentration to 2 M and digested with trypsin (substrate:enzyme = 40:1) at 37 °C overnight. Digested peptides were desalted using C18 columns and lyophilized. Peptide concentrations were measured using the colorimetric BCA peptide assay (Thermo Fisher Scientific). For TMT labeling, 100 µg of digested peptides was labeled with TMTpro 16-plex reagent at room temperature in the dark for 1 h. Reactions were stopped by addition of 5% hydroxylamine and incubation at room temperature in the dark for 15 min. Following labeling, peptide samples were pooled and lyophilized. The pooled samples were reconstituted in 0.1% TFA and fractionated using the high-pH reverse-phase peptide fractionation kit (Thermo Fisher Scientific) with nine elution buffers containing 0.1% triethylamine and 10%, 12.5%, 15%, 17.5%, 20%, 22.5%, 25%, 50%, and 75% acetonitrile, respectively. Fractions were lyophilized separately.</p>
<p>For ZMAT3-FLAG interacting protein identification, IP samples were solution digested with trypsin using S traps (Protifi), following the manufacturer’s instructions. Briefly, proteins were denatured in 5% SDS, 50 mM triethylammonium bicarbonate (TEAB) pH 8.5. They were next reduced with 5 mM Tris(2-carboxyethyl)phosphine (TCEP) and alkylated with 20 mM iodoacetamide. The proteins were acidified to a final concentration of 2.5% phosphoric acid and diluted into 100 mM TEAB pH 7.55 in 90% methanol. They were loaded onto the S-traps, washed four times with 100 mM TEAB pH 7.55 in 90% methanol, and digested with trypsin overnight at 37 °C. Peptides were eluted from the S-trap using 50 mM TEAB pH 8.5; 0.2% formic acid in water; and 50% acetonitrile in water. The elutions were pooled and dried by lyophilization.</p>
</sec>
<sec id="s4s">
<title>Mass Spectrometry Analysis</title>
<p>Dried peptides were resuspended in 5% acetonitrile, 0.05% TFA in water for mass spectrometry analysis on an Orbitrap Exploris 480 (Thermo) mass spectrometer. The peptides were separated on a 75 µm x 15 cm, 3 µm Acclaim PepMap reverse phase column (Thermo) at 300 nl/min using an UltiMate 3000 RSLCnano HPLC (Thermo) and eluted directly into the mass spectrometer. For analysis, parent full-scan mass spectra acquired at 120,000 FWHM resolution and product ion spectra at 45,000 resolutin with a 0.7 m/z isolation window. Proteome Discoverer 3.0 (Thermo) was used to search the data against the human database from Uniprot using SequestHT and with INFERYS rescoring. The search was limited to tryptic peptides, with maximally two missed cleavages allowed. Cysteine carbamidomethylation and TMT pro modification of lysine and peptide N-termini were set as a fixed modification, with methionine oxidation as a variable modification. The precursor mass tolerance was 10 ppm, and the fragment mass tolerance was 0.02 Da. The Percolator node was used to score and rank peptide matches using a 1% false discovery rate. TMT quantitation was performed using the Reporter Ions Quantifier nodes with correction of the values for lot-specific TMT reagent isotopic impurities.</p>
</sec>
<sec id="s4t">
<title>TCGA COAD gene expression</title>
<p>Gene expression and clinical data for COAD were obtained from The Cancer Genome Atlas (TCGA) using the TCGAbiolinks package (v2.16.0) in R (v4.0.0). The GDC query function was used to query samples by setting the data category to “gene expression,” data type to “gene expression quantification,” platform to “Illumina HiSeq,” file type to “normalized results,” and experimental strategy to “RNA-seq.” Data were then downloaded using GDC download followed by GDC prepare to obtain normalized gene expression values.</p>
</sec>
<sec id="s4u">
<title>Statistical analysis</title>
<p>Statistical analysis for all data was performed using data from at least three independent replicates. Difference between two groups were determined using a two-tailed Student’s t-test, while comparisons involving multiple groups were analyzed using two-way ANOVA.</p>
</sec>
</sec>

</body>
<back>
<sec id="s8" sec-type="data-availability">
<title>Data Availability</title>
<p>The RNA-seq data from <italic>ZMAT3</italic>-WT vs <italic>ZMAT3</italic>-KO HCT116 cells and from siCTRL vs sip53 from HCT116 have been deposited to GEO (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280756">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280756</ext-link>). The accession number is GSE280756.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We thank the CCR Genomics Core, CCR, NCI, Bethesda, MD for valuable assistance with Sanger sequencing and Agilent TapeStation. We also thank the CCR Sequencing Facility, NCI, Frederick, MD for performing the RNA-seq. Finally, we thank the members of the Lal lab for discussion and suggestions.</p>
</ack>
<sec id="additional-info" sec-type="additional-information">
<title>Additional information</title>
<sec id="s6">
<title>Author contribution statement</title>
<p>R.K and A.L designed experiments and interpreted the results. R.K., S.C., B.M., X.L and M.G performed experiments and analyzed data. R.C designed the gRNA constructs to KO ZMAT3. E.P., I.G., and X.W analyzed the RNA-seq data. L.J conducted the quantitative mass spectrometry. R.K., and A. L. wrote the manuscript.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>This research was supported by the Intramural Research Program (A.L.) of the National Cancer Institute (NCI), Center for Cancer Research (CCR), NIH (ZIA BC011646 to A.L.).</p>
</sec>
</sec>
<sec id="additional-files" sec-type="supplementary-material">
<title>Additional files</title>
<supplementary-material id="supp1">
<label>Figure Supplement 1-5</label>
    <caption>
        <p><bold>Figure 1- figure supplement 1</bold>.</p>
        <p><bold>(A)</bold> Immunoblotting of whole-cell lysates from <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells with or without Nutlin treatment for 24 h. GAPDH served as the loading control. <bold>(B)</bold> Incucyte live-cell proliferation assays of <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells. <bold>(C)</bold> GSEA of the top 500 significantly upregulated genes (p&lt;0.05) from RNA-seq comparing <italic>ZMAT3</italic>-KO versus <italic>ZMAT3</italic>-WT cells. <bold>(D)</bold> Volcano plot for the differentially expressed genes identified by RNA-Seq from <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells. Significantly expressed genes are indicated in red (p&lt;0.05).</p>
        <p><bold>Figure 2- figure supplement 1</bold>.</p>
        <p><bold>(A)</bold> Volcano plot of differentially expressed genes identified by RNA-Seq from HCT116 cells transfected with siCTRL or siZMAT3 for 72 h. Significantly differentially expressed genes (p&lt;0.05) are shown in red. <bold>(B)</bold> GSEA of the top 500 significantly upregulated genes (p&lt;0.05) upon <italic>ZMAT3</italic> knockdown with siRNAs in HCT116 cells identified by RNA-seq. <bold>(C, D)</bold> Venn diagrams showing overlap between the indicated RNA-Seq data sets. A total of 1,023 significant upregulated <bold>(C)</bold> and 1,042 significant downregulated <bold>(D)</bold> genes were shared between the <italic>ZMAT3</italic>-KO/<italic>ZMAT3</italic>-WT and siZMAT3/siCTRL comparisons. <bold>(E)</bold> Top significantly enriched pathways identified by GSEA of the top 500 most significantly upregulated genes (p&lt;0.05) commonly shared between the <italic>ZMAT3</italic>-KO/<italic>ZMAT3</italic>-WT and siZMAT3/siCTRL comparisons RNA-seq datasets. <bold>(F, G)</bold> Immunoblotting of whole-cell lysates from SW1222 and HCEC-1CT cells following siRNA-mediated knockdown of <italic>ZMAT3</italic> or <italic>HKDC1</italic> for 72 h. <italic>GAPDH</italic> served as the loading control. <bold>(H, I)</bold> <italic>ZMAT3</italic> and <italic>HKDC1</italic> mRNA levels in CRC patient samples from the TCGA COAD cohort comparing p53-WT (wild-type) and p53-mutant tumors. “N” denotes the number of samples in each group.</p>
        <p><bold>Figure 3- figure supplement 1</bold>.</p>
        <p>Non-mitochondrial oxygen consumption in HCT116 cells following <italic>ZMAT3</italic> and/or <italic>HKDC1</italic> knockdown. Error bars represent the mean ± SEM from four independent experiments.</p>
        <p><bold>Figure 4- figure supplement 1</bold>.</p>
        <p><bold>(A)</bold> Volcano plot showing differentially expressed genes identified by RNA-Seq from HCT116 cells transfected with si<italic>p53</italic> and siCTRL. Significantly expressed genes (p&lt;0.05) are shown in red. <bold>(B, C)</bold> Venn diagram showing genes commonly up- <bold>(B)</bold> or down-regulated <bold>(C)</bold> in RNA-Seq data following <italic>p53</italic> knockdown and <italic>ZMAT3</italic>-KO HCT116. <bold>(D, E)</bold> GSEA of genes commonly up-<bold>(D)</bold> or down-regulated <bold>(E)</bold> in RNA-Seq datasets from HCT116 upon <italic>p53</italic> knockdown and <italic>ZMAT3</italic>-KO.</p>
        <p><bold>Figure 5- figure supplement 1</bold>.</p>
        <p><bold>(A)</bold> RNA IPs followed by RT-qPCR were performed in biological triplicates in presence and absence of doxycycline in ZMAT3-FLAG-HA HCT116 cells. GAPDH served as a negative control. <bold>(B)</bold> Schematic representation of the full-length ZMAT3 protein showing three zinc finger motifs. Numbers indicate the position of the amino acids. <bold>(C)</bold> Immunoblotting was performed from 10% input and anti-FLAG IPs from doxycycline inducible ZMAT3-FLAG-HA HCT116 whole-cell lysates treated with or without doxycycline for 48 h. <bold>(D)</bold> IPs followed by immunoblotting using anti-FLAG beads and whole-cell lysates from untreated or doxycycline-treated ZMAT3-FLAG-HA HCT116 cells in presence or absence of DNase or RNase. Ten percent of total lysate was used as input. GAPDH was used as the loading control for input and negative control for the IPs.</p>
        <p><bold>Figure 5- figure supplement 2</bold>.</p>
        <p><bold>(A-D)</bold> IGV snapshot showing JUN, POLR2A, H3K27Ac and H3K4me3 ChIP-seq peaks at the <italic>LAMA2, VSNL1, SAMD3</italic> and <italic>IL6R</italic> loci from ENCODE cell line datasets (accession from top to bottom: ENCSR000FAH, ENCSR000EDG, ENCSR000EEK, ENCSR000EUU, ENCSR661KMA and ENCSR333OPW). The JUN binding motif (TGASTCA) is shown in blue (positive strand) and in red (negative strand). <bold>(E)</bold> <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells were transfected with CTRL siRNA or JUN siRNAs for 48 h, and RT-qPCR was performed. <italic>GAPDH</italic> served as the housekeeping gene control. <bold>(F)</bold> ChIP-qPCR was performed in biological triplicates using IgG control or anti-JUN antibody in <italic>ZMAT3</italic>-WT and <italic>ZMAT3-</italic>KO HCT116 cells.</p>
        <p><bold>Appendix 1</bold>.</p>
        <p><bold>(A-E)</bold> IGV snapshots showing JUN, POLR2A, H3K27Ac and H3K4me3 ChIP-seq peaks at the <italic>GLS, SREBF1, SLC2A1, CD36</italic> and <italic>WEE1</italic> locus from the ENCODE cell lines (accession from top to bottom: ENCSR000FAH, ENCSR000EDG, ENCSR000EEK, ENCSR000EUU, ENCSR661KMA and ENCSR333OPW). JUN binding motif (TGASTCA) is shown in blue (positive strand) and in red (negative strand). <bold>(F-H)</bold> RT-qPCR was performed from <italic>ZMAT</italic>3-WT and <italic>ZMAT3</italic>-KO HCT116 cells transfected with siCTRL or siJUN.</p>
        <p><bold>Appendix 2</bold>.</p>
        <p><bold>(A, B)</bold> Immunoblotting from <italic>ZMAT3</italic>-WT and <italic>ZMAT3</italic>-KO HCT116 cells in the absence or presence of Nutlin. GAPDH served as the loading control.</p></caption>
<media xlink:href="supplements/653341_file08.pdf"/>
</supplementary-material>
    <supplementary-material id="supp2">
        <label>Table S1</label>
    <media xlink:href="supplements/653341_file01.xlsx"/>
    </supplementary-material>
    <supplementary-material id="supp3">
        <label>Table S2</label>
        <media xlink:href="supplements/653341_file02.xlsx"/>
    </supplementary-material>
    <supplementary-material id="supp4">
        <label>Table S3</label>
        <media xlink:href="supplements/653341_file03.xlsx"/>
    </supplementary-material>
    <supplementary-material id="supp5">
        <label>Table S4</label>
        <media xlink:href="supplements/653341_file04.xlsx"/>
    </supplementary-material>
    <supplementary-material id="supp6">
        <label>Table S5</label>
        <media xlink:href="supplements/653341_file05.xlsx"/>
    </supplementary-material>
    <supplementary-material id="supp7">
        <label>Table S6</label>
        <media xlink:href="supplements/653341_file06.xlsx"/>
    </supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kandoth</surname>, <given-names>C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Mutational landscape and significance across 12 major cancer types</article-title>. <source>Nature</source> <volume>502</volume>, <fpage>333</fpage>–<lpage>339</lpage> (<year>2013</year>). <pub-id pub-id-type="doi">10.1038/nature12634</pub-id></mixed-citation></ref>
<ref id="c2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Olivier</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The IARC TP53 database: new online mutation analysis and recommendations to users</article-title>. <source>Hum Mutat</source> <volume>19</volume>, <fpage>607</fpage>–<lpage>614</lpage> (<year>2002</year>). <pub-id pub-id-type="doi">10.1002/humu.10081</pub-id></mixed-citation></ref>
<ref id="c3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Malkin</surname>, <given-names>D.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms</article-title>. <source>Science</source> <volume>250</volume>, <fpage>1233</fpage>–<lpage>1238</lpage> (<year>1990</year>). <pub-id pub-id-type="doi">10.1126/science.1978757</pub-id></mixed-citation></ref>
<ref id="c4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Oren</surname>, <given-names>M.</given-names></string-name> &amp; <string-name><surname>Prives</surname>, <given-names>C</given-names></string-name></person-group>. <article-title>p53: A tale of complexity and context</article-title>. <source>Cell</source> <volume>187</volume>, <fpage>1569</fpage>–<lpage>1573</lpage> (<year>2024</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2024.02.043</pub-id></mixed-citation></ref>
<ref id="c5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Donehower</surname>, <given-names>L. A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours</article-title>. <source>Nature</source> <volume>356</volume>, <fpage>215</fpage>–<lpage>221</lpage> (<year>1992</year>). <pub-id pub-id-type="doi">10.1038/356215a0</pub-id></mixed-citation></ref>
<ref id="c6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Donehower</surname>, <given-names>L. A</given-names></string-name></person-group>. <article-title>The p53-deficient mouse: a model for basic and applied cancer studies</article-title>. <source>Semin Cancer Biol</source> <volume>7</volume>, <fpage>269</fpage>–<lpage>278</lpage> (<year>1996</year>). <pub-id pub-id-type="doi">10.1006/scbi.1996.0035</pub-id></mixed-citation></ref>
<ref id="c7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boutelle</surname>, <given-names>A. M.</given-names></string-name> &amp; <string-name><surname>Attardi</surname>, <given-names>L. D</given-names></string-name></person-group>. <article-title>p53 and Tumor Suppression: It Takes a Network</article-title>. <source>Trends in cell biology</source> <volume>31</volume>, <fpage>298</fpage>–<lpage>310</lpage> (<year>2021</year>). <pub-id pub-id-type="doi">10.1016/j.tcb.2020.12.011</pub-id></mixed-citation></ref>
<ref id="c8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Indeglia</surname>, <given-names>A.</given-names></string-name> &amp; <string-name><surname>Murphy</surname>, <given-names>M. E</given-names></string-name></person-group>. <article-title>Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression</article-title>. <source>Crit Rev Biochem Mol Biol</source> <volume>59</volume>, <fpage>128</fpage>–<lpage>138</lpage> (<year>2024</year>). <pub-id pub-id-type="doi">10.1080/10409238.2024.2344465</pub-id></mixed-citation></ref>
<ref id="c9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Waldman</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Kinzler</surname>, <given-names>K. W.</given-names></string-name> &amp; <string-name><surname>Vogelstein</surname>, <given-names>B</given-names></string-name></person-group>. <article-title>p21 is necessary for the p53-mediated G1 arrest in human cancer cells</article-title>. <source>Cancer Res</source> <volume>55</volume>, <fpage>5187</fpage>–<lpage>5190</lpage> (<year>1995</year>).</mixed-citation></ref>
<ref id="c10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Kinzler</surname>, <given-names>K. W.</given-names></string-name>, <string-name><surname>Vogelstein</surname>, <given-names>B.</given-names></string-name> &amp; <string-name><surname>Zhang</surname>, <given-names>L</given-names></string-name></person-group>. <article-title>PUMA mediates the apoptotic response to p53 in colorectal cancer cells</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>100</volume>, <fpage>1931</fpage>–<lpage>1936</lpage> (<year>2003</year>). <pub-id pub-id-type="doi">10.1073/pnas.2627984100</pub-id></mixed-citation></ref>
<ref id="c11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shibue</surname>, <given-names>T.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Integral role of Noxa in p53-mediated apoptotic response</article-title>. <source>Genes Dev</source> <volume>17</volume>, <fpage>2233</fpage>–<lpage>2238</lpage> (<year>2003</year>). <pub-id pub-id-type="doi">10.1101/gad.1103603</pub-id></mixed-citation></ref>
<ref id="c12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Indeglia</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression</article-title>. <source>Cancer Discov</source> <volume>13</volume>, <fpage>1696</fpage>–<lpage>1719</lpage> (<year>2023</year>). <pub-id pub-id-type="doi">10.1158/2159-8290.CD-22-1315</pub-id></mixed-citation></ref>
<ref id="c13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Janic</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>DNA repair processes are critical mediators of p53-dependent tumor suppression</article-title>. <source>Nat Med</source> <volume>24</volume>, <fpage>947</fpage>–<lpage>953</lpage> (<year>2018</year>). <pub-id pub-id-type="doi">10.1038/s41591-018-0043-5</pub-id></mixed-citation></ref>
<ref id="c14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moon</surname>, <given-names>S. H.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression</article-title>. <source>Cell</source> <volume>176</volume>, <fpage>564</fpage>–<lpage>580.e519</lpage> (<year>2019</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2018.11.011</pub-id></mixed-citation></ref>
<ref id="c15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Suzuki</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>GLS2 Is a Tumor Suppressor and a Regulator of Ferroptosis in Hepatocellular Carcinoma</article-title>. <source>Cancer Res</source> <volume>82</volume>, <fpage>3209</fpage>–<lpage>3222</lpage> (<year>2022</year>). <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-21-3914</pub-id></mixed-citation></ref>
<ref id="c16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Valente</surname>, <given-names>L. J.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa</article-title>. <source>Cell Rep</source> <volume>3</volume>, <fpage>1339</fpage>–<lpage>1345</lpage> (<year>2013</year>). <pub-id pub-id-type="doi">10.1016/j.celrep.2013.04.012</pub-id></mixed-citation></ref>
<ref id="c17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bieging-Rolett</surname>, <given-names>K. T.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program</article-title>. <source>Mol Cell</source> <volume>80</volume>, <fpage>452</fpage>–<lpage>469.e459</lpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1016/j.molcel.2020.10.022</pub-id></mixed-citation></ref>
<ref id="c18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bieging-Rolett</surname>, <given-names>K. T.</given-names></string-name> &amp; <string-name><surname>Attardi</surname>, <given-names>L. D</given-names></string-name></person-group>. <article-title>Zmat3 splices together p53-dependent tumor suppression</article-title>. <source>Mol Cell Oncol</source> <volume>8</volume>, <issue>1898523</issue> (<year>2021</year>). <pub-id pub-id-type="doi">10.1080/23723556.2021.1898523</pub-id></mixed-citation></ref>
<ref id="c19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brennan</surname>, <given-names>M. S.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice</article-title>. <source>Cell Death Differ</source> <volume>31</volume>, <fpage>159</fpage>–<lpage>169</lpage> (<year>2024</year>). <pub-id pub-id-type="doi">10.1038/s41418-023-01250-w</pub-id></mixed-citation></ref>
<ref id="c20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Muys</surname>, <given-names>B. R.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The p53-induced RNA-binding protein ZMAT3 is a splicing regulator that inhibits the splicing of oncogenic CD44 variants in colorectal carcinoma</article-title>. <source>Genes Dev</source> <volume>35</volume>, <fpage>102</fpage>–<lpage>116</lpage> (<year>2021</year>). <pub-id pub-id-type="doi">10.1101/gad.342634.120</pub-id></mixed-citation></ref>
<ref id="c21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vilborg</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>106</volume>, <fpage>15756</fpage>–<lpage>15761</lpage> (<year>2009</year>). <pub-id pub-id-type="doi">10.1073/pnas.0900862106</pub-id></mixed-citation></ref>
<ref id="c22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bersani</surname>, <given-names>C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Genome-wide identification of Wig-1 mRNA targets by RIP-Seq analysis</article-title>. <source>Oncotarget</source> <volume>7</volume>, <fpage>1895</fpage>–<lpage>1911</lpage> (<year>2016</year>). <pub-id pub-id-type="doi">10.18632/oncotarget.6557</pub-id></mixed-citation></ref>
<ref id="c23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>, <given-names>B. C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Wig1 prevents cellular senescence by regulating p21 mRNA decay through control of RISC recruitment</article-title>. <source>EMBO J</source> <volume>31</volume>, <fpage>4289</fpage>–<lpage>4303</lpage> (<year>2012</year>). <pub-id pub-id-type="doi">10.1038/emboj.2012.286</pub-id></mixed-citation></ref>
<ref id="c24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bersani</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>L. D.</given-names></string-name>, <string-name><surname>Vilborg</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Lui</surname>, <given-names>W. O.</given-names></string-name> &amp; <string-name><surname>Wiman</surname>, <given-names>K. G</given-names></string-name></person-group>. <article-title>Wig-1 regulates cell cycle arrest and cell death through the p53 targets FAS and 14-3-3sigma</article-title>. <source>Oncogene</source> <volume>33</volume>, <fpage>4407</fpage>–<lpage>4417</lpage> (<year>2014</year>). <pub-id pub-id-type="doi">10.1038/onc.2013.594</pub-id></mixed-citation></ref>
<ref id="c25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khan</surname>, <given-names>M. W.</given-names></string-name>, <string-name><surname>Ding</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Cotler</surname>, <given-names>S. J.</given-names></string-name>, <string-name><surname>Clarke</surname>, <given-names>M.</given-names></string-name> &amp; <string-name><surname>Layden</surname>, <given-names>B. T</given-names></string-name></person-group>. <article-title>Studies on the Tissue Localization of HKDC1, a Putative Novel Fifth Hexokinase, in Humans</article-title>. <source>J Histochem Cytochem</source> <volume>66</volume>, <fpage>385</fpage>–<lpage>392</lpage> (<year>2018</year>). <pub-id pub-id-type="doi">10.1369/0022155418756849</pub-id></mixed-citation></ref>
<ref id="c26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cui</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>HKDC1, a target of TFEB, is essential to maintain both mitochondrial and lysosomal homeostasis, preventing cellular senescence</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>121</volume>, <fpage>e2306454120</fpage> (<year>2024</year>). <pub-id pub-id-type="doi">10.1073/pnas.2306454120</pub-id></mixed-citation></ref>
<ref id="c27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khan</surname>, <given-names>M. W.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The hexokinase “HKDC1” interaction with the mitochondria is essential for liver cancer progression</article-title>. <source>Cell Death Dis</source> <volume>13</volume>, <fpage>660</fpage> (<year>2022</year>). <pub-id pub-id-type="doi">10.1038/s41419-022-04999-z</pub-id></mixed-citation></ref>
<ref id="c28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zapater</surname>, <given-names>J. L.</given-names></string-name>, <string-name><surname>Wicksteed</surname>, <given-names>B.</given-names></string-name> &amp; <string-name><surname>Layden</surname>, <given-names>B. T</given-names></string-name></person-group>. <article-title>Enterocyte HKDC1 Modulates Intestinal Glucose Absorption in Male Mice Fed a High-fat Diet</article-title>. <source>Endocrinology</source> <volume>163</volume> (<year>2022</year>). <pub-id pub-id-type="doi">10.1210/endocr/bqac050</pub-id></mixed-citation></ref>
<ref id="c29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>, <given-names>X.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>HKDC1 promotes the tumorigenesis and glycolysis in lung adenocarcinoma via regulating AMPK/mTOR signaling pathway</article-title>. <source>Cancer Cell Int</source> <volume>20</volume>, <fpage>450</fpage> (<year>2020</year>). <pub-id pub-id-type="doi">10.1186/s12935-020-01539-7</pub-id></mixed-citation></ref>
<ref id="c30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>, <given-names>M. Q.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer</article-title>. <source>Cancer Sci</source> <volume>114</volume>, <fpage>1365</fpage>–<lpage>1377</lpage> (<year>2023</year>). <pub-id pub-id-type="doi">10.1111/cas.15692</pub-id></mixed-citation></ref>
<ref id="c31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boutelle</surname>, <given-names>A. M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Integrative multiomic approaches reveal ZMAT3 and p21 as conserved hubs in the p53 tumor suppression network</article-title>. <source>Cell Death Differ</source> (<year>2025</year>). <pub-id pub-id-type="doi">10.1038/s41418-025-01513-8</pub-id></mixed-citation></ref>
<ref id="c32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brayer</surname>, <given-names>K. J.</given-names></string-name> &amp; <string-name><surname>Segal</surname>, <given-names>D. J</given-names></string-name></person-group>. <article-title>Keep your fingers off my DNA: protein-protein interactions mediated by C2H2 zinc finger domains</article-title>. <source>Cell Biochem Biophys</source> <volume>50</volume>, <fpage>111</fpage>–<lpage>131</lpage> (<year>2008</year>). <pub-id pub-id-type="doi">10.1007/s12013-008-9008-5</pub-id></mixed-citation></ref>
<ref id="c33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gosztyla</surname>, <given-names>M. L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Integrated multi-omics analysis of zinc-finger proteins uncovers roles in RNA regulation</article-title>. <source>Mol Cell</source> (<year>2024</year>). <pub-id pub-id-type="doi">10.1016/j.molcel.2024.08.010</pub-id></mixed-citation></ref>
<ref id="c34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nabeel-Shah</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>C2H2-zinc-finger transcription factors bind RNA and function in diverse post-transcriptional regulatory processes</article-title>. <source>Mol Cell</source> <volume>84</volume>, <fpage>3810</fpage>–<lpage>3825.e3810</lpage> (<year>2024</year>). <pub-id pub-id-type="doi">10.1016/j.molcel.2024.08.037</pub-id></mixed-citation></ref>
<ref id="c35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Belgardt</surname>, <given-names>B. F.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Hypothalamic and pituitary c-Jun N-terminal kinase 1 signaling coordinately regulates glucose metabolism</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>107</volume>, <fpage>6028</fpage>–<lpage>6033</lpage> (<year>2010</year>). <pub-id pub-id-type="doi">10.1073/pnas.1001796107</pub-id></mixed-citation></ref>
<ref id="c36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xiao</surname>, <given-names>F.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Hepatic c-Jun regulates glucose metabolism via FGF21 and modulates body temperature through the neural signals</article-title>. <source>Mol Metab</source> <volume>20</volume>, <fpage>138</fpage>–<lpage>148</lpage> (<year>2019</year>). <pub-id pub-id-type="doi">10.1016/j.molmet.2018.12.003</pub-id></mixed-citation></ref>
<ref id="c37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scherer</surname>, <given-names>S. J.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV</article-title>. <source>J Biol Chem</source> <volume>275</volume>, <fpage>37469</fpage>–<lpage>37473</lpage> (<year>2000</year>). <pub-id pub-id-type="doi">10.1074/jbc.M006990200</pub-id></mixed-citation></ref>
<ref id="c38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eferl</surname>, <given-names>R.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53</article-title>. <source>Cell</source> <volume>112</volume>, <fpage>181</fpage>–<lpage>192</lpage> (<year>2003</year>). <pub-id pub-id-type="doi">10.1016/s0092-8674(03)00042-4</pub-id></mixed-citation></ref>
<ref id="c39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hellborg</surname>, <given-names>F.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein</article-title>. <source>Oncogene</source> <volume>20</volume>, <fpage>5466</fpage>–<lpage>5474</lpage> (<year>2001</year>). <pub-id pub-id-type="doi">10.1038/sj.onc.1204722</pub-id></mixed-citation></ref>
<ref id="c40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Varmeh-Ziaie</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Wig-1, a new p53-induced gene encoding a zinc finger protein</article-title>. <source>Oncogene</source> <volume>15</volume>, <fpage>2699</fpage>–<lpage>2704</lpage> (<year>1997</year>). <pub-id pub-id-type="doi">10.1038/sj.onc.1201454</pub-id></mixed-citation></ref>
<ref id="c41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cassandri</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Zinc-finger proteins in health and disease</article-title>. <source>Cell Death Discov</source> <volume>3</volume>, <fpage>17071</fpage> (<year>2017</year>). <pub-id pub-id-type="doi">10.1038/cddiscovery.2017.71</pub-id></mixed-citation></ref>
<ref id="c42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kamaliyan</surname>, <given-names>Z.</given-names></string-name> &amp; <string-name><surname>Clarke</surname>, <given-names>T. L</given-names></string-name></person-group>. <article-title>Zinc finger proteins: guardians of genome stability</article-title>. <source>Front Cell Dev Biol</source> <volume>12</volume>, <fpage>1448789</fpage> (<year>2024</year>). <pub-id pub-id-type="doi">10.3389/fcell.2024.1448789</pub-id></mixed-citation></ref>
<ref id="c43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Orth</surname>, <given-names>B.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Identification of an atypical interaction site in the BTB domain of the MYC-interacting zinc-finger protein 1</article-title>. <source>Structure</source> <volume>29</volume>, <fpage>1230</fpage>–<lpage>1240.e1235</lpage> (<year>2021</year>). <pub-id pub-id-type="doi">10.1016/j.str.2021.06.005</pub-id></mixed-citation></ref>
<ref id="c44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Font</surname>, <given-names>J.</given-names></string-name> &amp; <string-name><surname>Mackay</surname>, <given-names>J. P</given-names></string-name></person-group>. <article-title>Beyond DNA: zinc finger domains as RNA-binding modules</article-title>. <source>Methods Mol Biol</source> <volume>649</volume>, <fpage>479</fpage>–<lpage>491</lpage> (<year>2010</year>). <pub-id pub-id-type="doi">10.1007/978-1-60761-753-2_29</pub-id></mixed-citation></ref>
<ref id="c45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krishna</surname>, <given-names>S. S.</given-names></string-name>, <string-name><surname>Majumdar</surname>, <given-names>I.</given-names></string-name> &amp; <string-name><surname>Grishin</surname>, <given-names>N. V</given-names></string-name></person-group>. <article-title>Structural classification of zinc fingers: survey and summary</article-title>. <source>Nucleic Acids Res</source> <volume>31</volume>, <fpage>532</fpage>–<lpage>550</lpage> (<year>2003</year>). <pub-id pub-id-type="doi">10.1093/nar/gkg161</pub-id></mixed-citation></ref>
<ref id="c46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eferl</surname>, <given-names>R.</given-names></string-name> &amp; <string-name><surname>Wagner</surname>, <given-names>E. F</given-names></string-name></person-group>. <article-title>AP-1: a double-edged sword in tumorigenesis</article-title>. <source>Nat Rev Cancer</source> <volume>3</volume>, <fpage>859</fpage>–<lpage>868</lpage> (<year>2003</year>). <pub-id pub-id-type="doi">10.1038/nrc1209</pub-id></mixed-citation></ref>
<ref id="c47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname>, <given-names>C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia</article-title>. <source>Leukemia</source> <volume>31</volume>, <fpage>1196</fpage>–<lpage>1205</lpage> (<year>2017</year>). <pub-id pub-id-type="doi">10.1038/leu.2016.329</pub-id></mixed-citation></ref>
<ref id="c48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weiss</surname>, <given-names>C.</given-names></string-name> &amp; <string-name><surname>Bohmann</surname>, <given-names>D</given-names></string-name></person-group>. <article-title>Deregulated repression of c-Jun provides a potential link to its role in tumorigenesis</article-title>. <source>Cell Cycle</source> <volume>3</volume>, <fpage>111</fpage>–<lpage>113</lpage> (<year>2004</year>).</mixed-citation></ref>
<ref id="c49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Spangler</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Vardimon</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Bosserhoff</surname>, <given-names>A. K.</given-names></string-name> &amp; <string-name><surname>Kuphal</surname>, <given-names>S</given-names></string-name></person-group>. <article-title>Post-transcriptional regulation controlled by E-cadherin is important for c-Jun activity in melanoma</article-title>. <source>Pigment Cell Melanoma Res</source> <volume>24</volume>, <fpage>148</fpage>–<lpage>164</lpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1111/j.1755-148X.2010.00787.x</pub-id></mixed-citation></ref>
<ref id="c50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lively</surname>, <given-names>T. N.</given-names></string-name>, <string-name><surname>Ferguson</surname>, <given-names>H. A.</given-names></string-name>, <string-name><surname>Galasinski</surname>, <given-names>S. K.</given-names></string-name>, <string-name><surname>Seto</surname>, <given-names>A. G.</given-names></string-name> &amp; <string-name><surname>Goodrich</surname>, <given-names>J</given-names></string-name></person-group>. <article-title>A. c-Jun binds the N terminus of human TAF(II)250 to derepress RNA polymerase II transcription in vitro</article-title>. <source>J Biol Chem</source> <volume>276</volume>, <fpage>25582</fpage>–<lpage>25588</lpage> (<year>2001</year>). <pub-id pub-id-type="doi">10.1074/jbc.M100278200</pub-id></mixed-citation></ref>
<ref id="c51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xiao</surname>, <given-names>R.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Pervasive Chromatin-RNA Binding Protein Interactions Enable RNA-Based Regulation of Transcription</article-title>. <source>Cell</source> <volume>178</volume>, <fpage>107</fpage>–<lpage>121.e118</lpage> (<year>2019</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2019.06.001</pub-id></mixed-citation></ref>
<ref id="c52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuninger</surname>, <given-names>D. T.</given-names></string-name>, <string-name><surname>Izumi</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Papaconstantinou</surname>, <given-names>J.</given-names></string-name> &amp; <string-name><surname>Mitra</surname>, <given-names>S</given-names></string-name></person-group>. <article-title>Human AP-endonuclease 1 and hnRNP-L interact with a nCaRE-like repressor element in the AP-endonuclease 1 promoter</article-title>. <source>Nucleic Acids Res</source> <volume>30</volume>, <fpage>823</fpage>–<lpage>829</lpage> (<year>2002</year>). <pub-id pub-id-type="doi">10.1093/nar/30.3.823</pub-id></mixed-citation></ref>
<ref id="c53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wei</surname>, <given-names>C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>RBFox2 Binds Nascent RNA to Globally Regulate Polycomb Complex 2 Targeting in Mammalian Genomes</article-title>. <source>Mol Cell</source> <volume>62</volume>, <fpage>982</fpage> (<year>2016</year>). <pub-id pub-id-type="doi">10.1016/j.molcel.2016.06.003</pub-id></mixed-citation></ref>
<ref id="c54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ji</surname>, <given-names>X.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>SR proteins collaborate with 7SK and promoter-associated nascent RNA to release paused polymerase</article-title>. <source>Cell</source> <volume>153</volume>, <fpage>855</fpage>–<lpage>868</lpage> (<year>2013</year>). <pub-id pub-id-type="doi">10.1016/j.cell.2013.04.028</pub-id></mixed-citation></ref>
<ref id="c55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guo</surname>, <given-names>C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Coordinated regulatory variation associated with gestational hyperglycaemia regulates expression of the novel hexokinase HKDC1</article-title>. <source>Nat Commun</source> <volume>6</volume>, <fpage>6069</fpage> (<year>2015</year>). <pub-id pub-id-type="doi">10.1038/ncomms7069</pub-id></mixed-citation></ref>
<ref id="c56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>, <given-names>X.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>PGC1beta Regulates Breast Tumor Growth and Metastasis by SREBP1-Mediated HKDC1 Expression</article-title>. <source>Front Oncol</source> <volume>9</volume>, <fpage>290</fpage> (<year>2019</year>). <pub-id pub-id-type="doi">10.3389/fonc.2019.00290</pub-id></mixed-citation></ref>
<ref id="c57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Nian</surname>, <given-names>F.</given-names></string-name> &amp; <string-name><surname>Xu</surname>, <given-names>S</given-names></string-name></person-group>. <article-title>Identification of a glycolysis-related gene signature associated with clinical outcome for patients with lung squamous cell carcinoma</article-title>. <source>Cancer Med</source> <volume>10</volume>, <fpage>4017</fpage>–<lpage>4029</lpage> (<year>2021</year>). <pub-id pub-id-type="doi">10.1002/cam4.3945</pub-id></mixed-citation></ref>
<ref id="c58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bieging</surname>, <given-names>K. T.</given-names></string-name>, <string-name><surname>Mello</surname>, <given-names>S. S.</given-names></string-name> &amp; <string-name><surname>Attardi</surname>, <given-names>L. D</given-names></string-name></person-group>. <article-title>Unravelling mechanisms of p53-mediated tumour suppression</article-title>. <source>Nat Rev Cancer</source> <volume>14</volume>, <fpage>359</fpage>–<lpage>370</lpage> (<year>2014</year>). <pub-id pub-id-type="doi">10.1038/nrc3711</pub-id></mixed-citation></ref>
<ref id="c59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vousden</surname>, <given-names>K. H.</given-names></string-name> &amp; <string-name><surname>Ryan</surname>, <given-names>K. M</given-names></string-name></person-group>. <article-title>p53 and metabolism</article-title>. <source>Nat Rev Cancer</source> <volume>9</volume>, <fpage>691</fpage>–<lpage>700</lpage> (<year>2009</year>). <pub-id pub-id-type="doi">10.1038/nrc2715</pub-id></mixed-citation></ref>
<ref id="c60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tarangelo</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells</article-title>. <source>Cell Rep</source> <volume>22</volume>, <fpage>569</fpage>–<lpage>575</lpage> (<year>2018</year>). <pub-id pub-id-type="doi">10.1016/j.celrep.2017.12.077</pub-id></mixed-citation></ref>
<ref id="c61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cairns</surname>, <given-names>R. A.</given-names></string-name>, <string-name><surname>Harris</surname>, <given-names>I. S.</given-names></string-name> &amp; <string-name><surname>Mak</surname>, <given-names>T. W</given-names></string-name></person-group>. <article-title>Regulation of cancer cell metabolism</article-title>. <source>Nat Rev Cancer</source> <volume>11</volume>, <fpage>85</fpage>–<lpage>95</lpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1038/nrc2981</pub-id></mixed-citation></ref>
<ref id="c62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pavlova</surname>, <given-names>N. N.</given-names></string-name> &amp; <string-name><surname>Thompson</surname>, <given-names>C. B</given-names></string-name></person-group>. <article-title>The Emerging Hallmarks of Cancer Metabolism</article-title>. <source>Cell Metab</source> <volume>23</volume>, <fpage>27</fpage>–<lpage>47</lpage> (<year>2016</year>). <pub-id pub-id-type="doi">10.1016/j.cmet.2015.12.006</pub-id></mixed-citation></ref>
<ref id="c63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wolpaw</surname>, <given-names>A. J.</given-names></string-name> &amp; <string-name><surname>Dang</surname>, <given-names>C. V</given-names></string-name></person-group>. <article-title>Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy</article-title>. <source>Trends in cell biology</source> <volume>28</volume>, <fpage>201</fpage>–<lpage>212</lpage> (<year>2018</year>). <pub-id pub-id-type="doi">10.1016/j.tcb.2017.11.006</pub-id></mixed-citation></ref>
<ref id="c64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schwartzenberg-Bar-Yoseph</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Armoni</surname>, <given-names>M.</given-names></string-name> &amp; <string-name><surname>Karnieli</surname>, <given-names>E</given-names></string-name></person-group>. <article-title>The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression</article-title>. <source>Cancer Res</source> <volume>64</volume>, <fpage>2627</fpage>–<lpage>2633</lpage> (<year>2004</year>). <pub-id pub-id-type="doi">10.1158/0008-5472.can-03-0846</pub-id></mixed-citation></ref>
<ref id="c65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Franklin</surname>, <given-names>D. A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>p53 coordinates DNA repair with nucleotide synthesis by suppressing PFKFB3 expression and promoting the pentose phosphate pathway</article-title>. <source>Sci Rep</source> <volume>6</volume>, <issue>38067</issue> (<year>2016</year>). <pub-id pub-id-type="doi">10.1038/srep38067</pub-id></mixed-citation></ref>
<ref id="c66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ros</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells</article-title>. <source>Oncogene</source> <volume>36</volume>, <fpage>3287</fpage>–<lpage>3299</lpage> (<year>2017</year>). <pub-id pub-id-type="doi">10.1038/onc.2016.477</pub-id></mixed-citation></ref>
<ref id="c67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth</article-title>. <source>Cell Rep</source> <volume>8</volume>, <fpage>1461</fpage>–<lpage>1474</lpage> (<year>2014</year>). <pub-id pub-id-type="doi">10.1016/j.celrep.2014.07.053</pub-id></mixed-citation></ref>
<ref id="c68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ravi</surname>, <given-names>R.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha</article-title>. <source>Genes Dev</source> <volume>14</volume>, <fpage>34</fpage>–<lpage>44</lpage> (<year>2000</year>).</mixed-citation></ref>
<ref id="c69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jiang</surname>, <given-names>P.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase</article-title>. <source>Nat Cell Biol</source> <volume>13</volume>, <fpage>310</fpage>–<lpage>316</lpage> (<year>2011</year>). <pub-id pub-id-type="doi">10.1038/ncb2172</pub-id></mixed-citation></ref>
<ref id="c70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shalem</surname>, <given-names>O.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Genome-scale CRISPR-Cas9 knockout screening in human cells</article-title>. <source>Science</source> <volume>343</volume>, <fpage>84</fpage>–<lpage>87</lpage> (<year>2014</year>). <pub-id pub-id-type="doi">10.1126/science.1247005</pub-id></mixed-citation></ref>
<ref id="c71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andrysik</surname>, <given-names>Z.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity</article-title>. <source>Genome Res</source> <volume>27</volume>, <fpage>1645</fpage>–<lpage>1657</lpage> (<year>2017</year>). <pub-id pub-id-type="doi">10.1101/gr.220533.117</pub-id></mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107538.2.sa3</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Wenwei</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/05vt9qd57</institution-id><institution>Rutgers, The State University of New Jersey</institution>
</institution-wrap>
<city>New Brunswick</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Convincing</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Fundamental</kwd>
</kwd-group>
</front-stub>
<body>
<p>In this study, the authors investigate the role of ZMAT3, a p53 target gene, in tumor suppression and RNA splicing regulation. Using quantitative proteomics, the authors uncover that ZMAT3 knockout leads to upregulation of HKDC1, a gene linked to mitochondrial respiration, and that ZMAT3 suppresses HKDC1 expression by inhibiting c-JUN-mediated transcription. This set of <bold>convincing</bold> evidence reveals a <bold>fundamental</bold> mechanism by which ZMAT3 contributes to p53-driven tumor suppression by regulating mitochondrial respiration.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107538.2.sa2</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>ZMAT3 is a p53 target gene that the Lal group and others have shown is important for p53-mediated tumor suppression, and which plays a role in the control of RNA splicing. In this manuscript Lal and colleagues perform quantitative proteomics of cells with ZMAT3 knockout and show that the enzyme hexokinase HKDC1 is the most upregulated protein. Mechanistically, the authors show that ZMAT3 does not appear to directly regulate the expression of HKDC1; rather, they show that the transcription factor c-JUN was strongly enriched in ZMAT3 pull-downs in IP-mass spec experiments, and they perform IP-western to demonstrate an interaction between c-JUN and ZMAT3. Importantly, the authors demonstrate, using ChIP-qPCR, that JUN is present at the HKDC1 gene (intron 1) in ZMAT3 WT cells, and showed markedly enhanced binding in ZMAT3 KO cells. The data best fit a model whereby p53 transactivates ZMAT3, leading to decreased JUN binding to the HKDC1 promoter, and altered mitochondrial respiration. The data are novel, compelling and very interesting.</p>
<p>Comments on revisions:</p>
<p>The authors have done a thorough job addressing my comments. This manuscript is quite strong and will be highly cited for its novelty and rigor.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107538.2.sa1</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>The study elucidates the role of the recently discovered mediator of p53 tumor suppressive activity, ZMAT3. Specifically, the authors find that ZMAT3 negatively regulates HKDC1, a gene involved in the control of mitochondrial respiration and cell proliferation.</p>
<p>Comments on revisions:</p>
<p>The authors have mostly addressed to the concerns raised previously by this reviewer. The lack of functional assays made the reported findings mostly mechanistic with no clear biological context.</p>
<p>The present manuscript is certainly improved compared to the previous version.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107538.2.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kumar</surname>
<given-names>Ravi</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Couly</surname>
<given-names>Simon</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Muys</surname>
<given-names>Bruna R</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Xiao Ling</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Grammatikakis</surname>
<given-names>Ioannis</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8455-1584</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Singh</surname>
<given-names>Ragini</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guest</surname>
<given-names>Mary</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wen</surname>
<given-names>Xinyu</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tang</surname>
<given-names>Wei</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ambs</surname>
<given-names>Stefan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jenkins</surname>
<given-names>Lisa M</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1245-1338</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Pehrsson</surname>
<given-names>Erica C</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chari</surname>
<given-names>Raj</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Su</surname>
<given-names>Tsung-Ping</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lal</surname>
<given-names>Ashish</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4299-8177</contrib-id></contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the original reviews.</p>
<disp-quote content-type="editor-comment">
<p><bold>Public Reviews:</bold></p>
<p><bold>Reviewer #1 (Public review):</bold></p>
<p>Summary:</p>
<p>ZMAT3 is a p53 target gene that the Lal group and others have shown is important for p53mediated tumor suppression, and which plays a role in the control of RNA splicing. In this manuscript, Lal and colleagues perform quantitative proteomics of cells with ZMAT3 knockout and show that the enzyme hexokinase HKDC1 is the most upregulated protein. Mechanistically, the authors show that ZMAT3 does not appear to directly regulate the expression of HKDC1; rather, they show that the transcription factor c-JUN was strongly enriched in ZMAT3 pull-downs in IP-mass spec experiments, and they perform IP-western to demonstrate an interaction between c-JUN and ZMAT3. Importantly, the authors demonstrate, using ChIP-qPCR, that JUN is present at the HKDC1 gene (intron 1) in ZMAT3 WT cells and shows markedly enhanced binding in ZMAT3 KO cells. The data best fit a model whereby p53 transactivates ZMAT3, leading to decreased JUN binding to the HKDC1 promoter, and altered mitochondrial respiration.</p>
<p>Strengths:</p>
<p>The authors use multiple orthogonal approaches to test the majority of their findings.  The authors offer a potentially new activity of ZMAT3 in tumor suppression by p53: the control of mitochondrial respiration.</p>
<p>Weaknesses:</p>
<p>Some indication as to whether other c-JUN target genes are also regulated by ZMAT3 would improve the broad relevance of the authors' findings.</p>
</disp-quote>
<p>We thank the reviewer for the kind words and the thoughtful suggestion. As recommended, to identify additional c-JUN targets potentially regulated by ZMAT3, we intersected the genes upregulated upon ZMAT3 knockout (from our RNA-seq data) with the ChIP-Atlas dataset for human c-JUN and cross-referenced these with c-JUN peaks from three ENCODE cell lines. From this analysis, we selected for further analysis the top 4 candidate genes - LAMA2, VSNL1, SAMD3, and IL6R (Figure 5-figure supplement 2A-D). Like HKDC1, these genes were upregulated in ZMAT3-KO cells, and this upregulation was abolished upon siRNA-mediated JUN knockdown in ZMAT3-KO cells (Figure 5-figure supplement 2E). Moreover, by ChIP-qPCR we observed increased JUN binding to the JUN peak for these genes in ZMAT3-KO cells as compared to the ZMAT3-WT (Figure 5- figure supplement 2F). As described on page 11 of the revised manuscript, these results suggest that the ZMAT3/JUN axis negatively regulates HKDC1 expression and additional c-JUN target genes.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Public review):</bold></p>
<p>Summary:</p>
<p>The study elucidates the role of the recently discovered mediator of p53 tumor suppressive activity, ZMAT3. Specifically, the authors find that ZMAT3 negatively regulates HKDC1, a gene involved in the control of mitochondrial respiration and cell proliferation.</p>
<p>Strengths:</p>
<p>Mechanistically, ZMAT3 suppresses HKDC1 transcription by sequestering JUN and preventing its binding to the HKDC1 promoter, resulting in reduced HKDC1 expression. Conversely, p53 mutation leads to ZMAT3 downregulation and HKDC1 overexpression, thereby promoting increased mitochondrial respiration and proliferation. This mechanism is novel; however, the authors should address several points.</p>
<p>Weaknesses:</p>
<p>The authors conduct mechanistic experiments (e.g., transcript and protein quantification, luciferase assays) to demonstrate regulatory interactions between p53, ZMAT3, JUN, and HKDC1. These findings should be supported with functional assays, such as proliferation, apoptosis, or mitochondrial respiration analyses.</p>
</disp-quote>
<p>We thank the reviewer for appreciating our work and for this valuable suggestion. The reviewer rightly pointed out that supporting the regulatory interactions between p53, ZMAT3, JUN and HKDC1 with functional assays such as proliferation, apoptosis and mitochondrial respiration analyses would strengthen our mechanistic data. During the revision of our manuscript, we attempted to address this point by performing simultaneously knockdown of these proteins; however, we observed substantial toxicity under these conditions, making the functional assays technically unfeasible. This outcome was not unexpected as knockdown of JUN or HKDC1 individually results in growth defects.  We therefore focused our efforts on addressing the recommendation for authors.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #3 (Public review):</bold></p>
<p>Summary:</p>
<p>In their manuscript, Kumar et al. investigate the mechanisms underlying the tumor suppressive function of the RNA binding protein ZMAT3, a previously described tumor suppressor in the p53 pathway. To this end, they use RNA-sequencing and proteomics to characterize changes in ZMAT3-deficient cells, leading them to identify the hexokinase HKDC1 as upregulated with ZMAT3 deficiency first in colorectal cancer cells, then in other cell types of both mouse and human origin. This increase in HKDC1 is associated with increased mitochondrial respiration. As ZMAT3 has been reported as an RNA-binding and DNA-binding protein, the authors investigated this via PAR-CLIP and ChIP-seq but did not observe ZMAT3 binding to HKDC1 pre-mRNA or DNA. Thus, to better understand how ZMAT3 regulates HKDC1, the authors used quantitative proteomics to identify ZMAT3interacting proteins. They identified the transcription factor JUN as a ZMAT3-interacting protein and showed that JUN promotes the increased HKDC1 RNA expression seen with ZMAT3 inactivation. They propose that ZMAT3 inhibits JUN-mediated transcriptional induction of HKDC1 as a mechanism of tumor suppression. This work uncovers novel aspects of the p53 tumor suppressor pathway.</p>
<p>Strengths:</p>
<p>This novel work sheds light on one of the most well-established yet understudied p53 target genes, ZMAT3, and how it contributes to p53's tumor suppressive functions. Overall, this story establishes a p53-ZMAT3-HKDC1 tumor suppressive axis, which has been strongly substantiated using a variety of orthogonal approaches, in different cell lines and with different data sets.</p>
<p>Weaknesses:</p>
<p>While the role of p53 and ZMAT3 in repressing HKDC1 is well substantiated, there is a gap in understanding how ZMAT3 acts to repress JUN-driven activation of the HKDC1 locus. How does ZMAT3 inhibit JUN binding to HKDC1? Can targeted ChIP experiments or RIP experiments be used to make a more definitive model? Can ZMAT3 mutants help to understand the mechanisms? Future work can further establish the mechanisms underlying how ZMAT3 represses JUN activity.</p>
</disp-quote>
<p>We thank the reviewer for the kind words and the invaluable suggestion. The reviewer has an excellent point regarding how ZMAT3 inhibits JUN binding to HKDC1 locus.Our new data included in the revised manuscript show that the ZMAT3-JUN interaction is lost in the presence of DNase or RNase, indicating that the interaction requires both DNA and RNA. This result suggests that ZMAT3 and JUN  form an RNA-dependent, chromatin- associated complex. Although not directly investigated in our study, this finding is consistent with emerging evidence that RBPs can function as chromatin-associated cofactors in transcription. For example, functional interplay between transcription factor YY1 and the RNA binding protein RBM25 co-regulates a broad set of genes, where RBM25 appears to engage promoters first and then recruit YY1, with RNA proposed to guide target recognition. We have discussed this possibility in the discussion section of revised manuscript (page 13). We agree that future work using ZMAT3 mutants and targeted ChIP or RIP assays will be valuable to delineate the precise mechanism by which ZMAT3 inhibits JUN binding to its target genes.</p>
<disp-quote content-type="editor-comment">
<p><bold>Recommendations for the authors:</bold></p>
<p><bold>Reviewer #1 (Recommendations for the authors):</bold></p>
<p>ZMAT3 is a p53 target gene that the Lal group and others have shown is important for p53mediated tumor suppression, and which plays a role in the control of RNA splicing. In this manuscript, Lal and colleagues perform quantitative proteomics of cells with ZMAT3 knockout and show that the enzyme hexokinase HKDC1 is the most upregulated protein. HKDC1 is emerging as an important player in human cancer. Importantly, the authors show both acute (gene silencing) and chronic (CRISPR KO) approaches to silence ZMAT3, and they do this in several cell lines. Notably, they show that ZMAT3 silencing leads to impaired mitochondrial respiration, in a manner that is rescued by silencing of HKDC1. Mechanistically, the authors show that ZMAT3 does not appear to directly regulate the expression of HKDC1; rather, they show that the transcription factor c-JUN was strongly enriched in ZMAT3 pull-downs in IP-mass spec experiments, and they perform IP-western to demonstrate an interaction between c-JUN and ZMAT3. Importantly, the authors demonstrate, using ChIP-qPCR, that JUN is present at the HKDC1 gene (intron 1) in ZMAT3 WT cells, and shows markedly enhanced binding in ZMAT3 KO cells. The data best fit a model whereby p53 transactivates ZMAT3, leading to decreased JUN binding to the HKDC1 promoter (intron 1), and altered mitochondrial respiration. The findings are compelling, and the authors use multiple orthogonal approaches to test most findings. And the authors offer a potentially new activity of ZMAT3 in tumor suppression by p53: the control of mitochondrial respiration. As such, enthusiasm is high for this manuscript.</p>
<p>Addressing the following question would improve the manuscript.</p>
<p>It is not clear how many (other) c-JUN target genes might be impacted by ZMAT3; other important c-JUN targets in cancer include GLS1, WEE1, SREBP1, GLUT1, and CD36, so there could be a global impact on metabolism in ZMAT3 KO cells. Can the authors perform qPCR on these targets in ZMAT3 WT and KO cells and see if these target genes are differentially expressed?</p>
</disp-quote>
<p>We thank the reviewer for this thoughtful suggestion. As recommended, we examined the expression of key c-JUN target genes GLS1 (also known as GLS), WEE1, SREBP1, GLUT1, and CD36 in ZMAT3-WT and ZMAT3-KO cells. We first analyzed publicly available JUN ChIP-Seq data from three ENCODE cell lines, which revealed JUN binding peaks near or upstream of exon 1 for GLS1/GLS, SREBP1, and SLC2A1/GLUT1, but not for WEE1 or CD36 (Appendix 1, panels A-E). Based on these results, we performed RT-qPCR for GLS1/GLS, SREBP1 and SLC2A1 in ZMAT3-WT and ZMAT3-KO cells, with or without JUN knockdown. GLS mRNA was significantly reduced upon JUN knockdown in both ZMAT3-WT cells and ZMAT3-KO cells, but it was not upregulated upon loss of ZMAT3, indicating that GLS is a JUN target gene, but it is not regulated by ZMAT3. In contrast, SREBF1 or SLC2A1 expression remained unchanged upon ZMAT3 loss or JUN knockdown (Appendix 1 panels F-H). These data suggest that the ZMAT3/JUN axis does not regulate the expression of these genes.</p>
<p>To identify additional c-JUN targets potentially regulated by ZMAT3, we intersected the genes upregulated upon ZMAT3 knockout (from our RNA-seq data) with the ChIP-Atlas dataset for human c-JUN and cross-referenced these with c-JUN peaks from three ENCODE cell lines. From this analysis, we selected for further analysis the top 4 candidate genes - LAMA2, VSNL1, SAMD3, and IL6R (Figure 5-figure supplement 2A-D). Like HKDC1, these genes were upregulated in ZMAT3-KO cells, and this upregulation was abolished upon siRNA-mediated JUN knockdown in ZMAT3-KO cells (Figure 5-figure supplement 2E). Moreover, by ChIP-qPCR we observed increased JUN binding to the JUN peak for these genes in ZMAT3-KO cells as compared to the ZMAT3-WT (Figure 5- figure supplement 2F). As described on page 11 of the revised manuscript, these results suggest that the ZMAT3/JUN axis negatively regulates HKDC1 expression and additional c-JUN target genes.</p>
<disp-quote content-type="editor-comment">
<p>Minor concerns:</p>
<p>(1) Line 150: observed a modest.</p>
<p>(2) Line 159: Figure 2G appears to be inaccurately cited.</p>
<p>(3) Line 191: assays to measure.</p>
</disp-quote>
<p>We thank the reviewer for pointing these out. These minor concerns have been addressed in the text.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Recommendations for the authors):</bold></p>
<p>(1) Figure 1E: Can the authors clarify what the numbers on the left side of the chart represent? Do they refer to the scale?</p>
</disp-quote>
<p>The numbers on the Y-axis represent the -log 10 (p- value) where higher values correspond to more significant changes. For visualization purposes, the significant changes are shown in red.</p>
<disp-quote content-type="editor-comment">
<p>(2) Page 5, line 123: The sentence &quot;As expected, ZMAT3 mRNA levels were decreased in the ZMAT3-KO cells&quot; is redundant, as this information was already mentioned on page 4, line 103.</p>
</disp-quote>
<p>We thank the reviewer for noticing this redundancy. The repeated sentence has been removed in the revised manuscript.</p>
<disp-quote content-type="editor-comment">
<p>(3) Page 5: The authors state: &quot;Transcriptome-wide, upon loss of ZMAT3, 606 genes were significantly up-regulated (adj. p &lt; 0.05 and 1.5-fold change) and 552 were down-regulated, with a median fold change of 1.76 and 0.55 for the up- and down-regulated genes, respectively.&quot; Later, on page 6, they write: &quot;Comparison of the RNA-seq data from ZMAT3WT vs. ZMAT3-KO and CTRL siRNA vs. ZMAT3 siRNA-transfected HCT116 cells indicated that 1023 genes were commonly up-regulated, and 1042 were commonly down-regulated upon ZMAT3 loss (Figure S2C and D).&quot; Why is the number of deregulated transcripts higher in the ZMAT3-WT vs. ZMAT3-KO comparison than in the CTRL siRNA vs. ZMAT3 siRNA comparison? Are the authors using less stringent criteria in the second analysis? This point should be clarified.</p>
</disp-quote>
<p>We thank the reviewer for highlighting this point. The reviewer is correct that less stringent criteria were used in the second analysis. On page 5, we applied stringent thresholds (adjusted p-value &lt; 0.05 and 1.5-fold change) to identify high-confidence transcriptome-wide changes upon ZMAT3 loss. In contrast, for the comparison of both RNA-seq datasets (ZMAT3-WT vs. KO and siCTRL vs. siZMAT3), we included genes that were consistently up- or downregulated, without applying a fold change threshold, focusing instead on significantly altered genes (adjusted p &lt; 0.05) in both datasets. This allowed us to capture broader and more reproducible transcriptomic changes that occur upon ZMAT3 depletion, including modest but significant changes upon transient ZMAT3 knockdown with siRNAs. We have now clarified this distinction on page 6 of the revised manuscript.</p>
<disp-quote content-type="editor-comment">
<p>(4) Figures 2B and 2E: The authors should provide quantification of HKDC1 protein levels normalized to a loading control. In addition, they should assess HKDC1 protein abundance upon ZMAT3 interference in SWI1222 and HCEC1CT cells, not just in HepG2 and HCT116 cells.</p>
</disp-quote>
<p>We thank the reviewer for this suggestion. We have now quantified all immunoblots presented throughout the manuscript, including those shown in Figures 2B and 2E, and all other figures containing protein analyses. Band intensities were quantified using ImageJ densitometry and normalized to GAPDH as the loading control. In addition, as suggested, we examined HKDC1 protein levels following ZMAT3 knockdown in two additional cell lines, SW1222 and HCEC-1CT. Consistent with our observations in HepG2 and HCT116 cells, ZMAT3 depletion led to increased HKDC1 protein levels in both SW1222 and HCEC-1CT cells. These new data are now included in Figure 2-figure supplement 1F and G. We have updated the Results section, figure legends, and figures to reflect these additions.</p>
<disp-quote content-type="editor-comment">
<p>(5) Figure 3A: It is unclear which gene was knocked out in the &quot;KO cells.&quot; The authors should clearly specify this.</p>
</disp-quote>
<p>We thank the reviewer for pointing this out. We have now updated Figure 3A.</p>
<disp-quote content-type="editor-comment">
<p>(6) Figure 3D: The result appears counterintuitive in comparison to Figure 3E. Why does HKDC1 knockdown reduce cell confluency more in ZMAT3 KO cells than in control (ZMAT3 wild-type) cells? The authors should explain this discrepancy more clearly.</p>
</disp-quote>
<p>We thank the reviewer for this insightful comment. As shown in Figure 3D and 3E, knockdown of HKDC1 resulted in a greater decrease in proliferation in ZMAT3-KO cells than in ZMAT3-WT cells. This observation was indeed unexpected, given that HKDC1 acts downstream of ZMAT3. One possible explanation is that elevated HKDC1 expression in ZMAT3-KO cells increases their reliance on HKDC1 for sustaining proliferation, and that HKDC1 may also participate in additional pathways in ZMAT3-KO cells. Consequently, transient knockdown of HKDC1 in ZMAT3-KO cells would have a more pronounced effect on proliferation due to their increased dependency on HKDC1 activity. In contrast, ZMAT3WT cells which express lower levels of HKDC1 are less dependent on its function and therefore less sensitive to its depletion. We have now clarified this point on page 8 of the revised manuscript.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #3 (Recommendations for the authors):</bold></p>
<p>(1) Why do the authors start their analysis by knocking out the p53 response element in Zmat3? That should be clarified. In addition, since clones were picked after CRISPR KO of Zmat3, were experiments done to confirm that p53 signaling was not disrupted?</p>
</disp-quote>
<p>We thank the reviewer for this thoughtful question. We began our study by targeting the p53 response element (p53RE) in the ZMAT3 locus because the basal expression of ZMAT3 is regulated by p53 (Muys, Bruna R. et al., Genes &amp; Development, 2021). Deleting the p53RE therefore allowed us to markedly reduce ZMAT3 expression without disrupting the entire ZMAT3 locus. We have clarified this rationale on page 4 of the revised manuscript. To ensure that p53 signaling was not affected by this modification, we verified that canonical p53 targets such as p21 were equivalently induced in both ZMAT3WT and KO cells following Nutlin treatment and that p53 induction was unchanged(Figure 4F and Figure 1 – figure supplement 1A).</p>
<disp-quote content-type="editor-comment">
<p>(2) Throughout the text, many immunoblots are used to validate the knockouts and knockdowns used, but some clarification is needed. In Figure S1A, the Zmat3-WT sample seems to have significantly more p53 than the Zmat3 KO sample. Does Zmat3 KO compromise p53 levels in other experiments? It would be good to understand if Zmat3 affects p53 function by affecting its levels. Also, the p21 blot is overloaded.</p>
</disp-quote>
<p>We thank the reviewer for this helpful observation. To determine whether ZMAT3 knockout affects p53 function by affecting its levels, we repeated the experiment three independent times. Western blots from these biological replicates, together with protein quantification, are now included in Appendix-2 and Figure 1-figure supplement 1A. These data show no significant differences in p53 or p21 induction between ZMAT3-WT and ZMAT3-KO cells following Nutlin treatment. In the revised manuscript, we have replaced the blot in Figure 1-figure supplement 1A with a more representative image from one of these replicate experiments.</p>
<disp-quote content-type="editor-comment">
<p>In Figure 2E, HKDC1 protein levels are not shown for the SW1222 and HCEC-1CT cell lines,</p>
</disp-quote>
<p>We thank the reviewer for this suggestion. HKDC1 protein levels in SW1222 and HCEC1-CT cells following ZMAT3 knockdown are now included as Figure 2- figure supplement 1F and 1G, together with the corresponding quantification.</p>
<disp-quote content-type="editor-comment">
<p>and Zmat3 does not appear as its characteristic two bands on the blot. What does this signify?</p>
</disp-quote>
<p>We thank the reviewer for this observation. Endogenous ZMAT3 typically appears as two closely migrating bands on immunoblots. As shown in Figure 4D and Appendix 2A and 2B, these two bands are observed at the expected molecular weight following Nutlin treatment and are specific to ZMAT3, as they are markedly reduced in ZMAT3-KO cells. In contrast, only a single ZMAT3 band is visible in Figure 2E. This likely reflects limited resolution of the two bands in some blots rather than a biological difference.</p>
<disp-quote content-type="editor-comment">
<p>(3) Why does HKDC1 knockdown only have an effect on metabolic phenotypes when ZMAT3 is gone? In Figure 3A, there does not seem to be a decrease in hexokinase activity in the siCTRL + siHKDC1 condition compared to siCTRL alone. Also, in Figure 3A, does phosphorylation activity of HKDC1 necessarily reflect glucose uptake, as stated? Additionally, in Figure 3C, there is no effect on mitochondrial respiration with siHKDC1, even though recent studies have shown a significant effect of HKDC1 on this.</p>
</disp-quote>
<p>We thank the reviewer for raising these important questions. As noted, HKDC1 knockdown alone in wild-type cells (siCTRL + siHKDC1) does not significantly reduce hexokinase activity (Figure 3A). This likely reflects the low basal expression of HKDC1 in these cells. Thus, the metabolic phenotype may only become apparent when HKDC1 expression exceeds a functional threshold, as observed in ZMAT3-KO cells where HKDC1 is upregulated.</p>
<p>Regarding the glucose uptake assay, HKDC1 itself is not phosphorylated; rather, it phosphorylates a non-catabolizable glucose analog, 2-deoxyglucose (2-DG) upon cellular uptake. According to the manufacturer’s protocol, intracellular 2-DG is phosphorylated by hexokinases to 2-deoxyglucose-6-phosphate (2-DG6P), which cannot be further metabolized and therefore accumulates. The accumulated 2-DG6P is quantified using a luminescence-based readout. This assay is widely used as a surrogate for glucose uptake because it reflects both glucose import and phosphorylation — the first step of glycolytic flux. As for the lack of change in mitochondrial respiration (Figure 3C), we acknowledge that some studies have reported mitochondrial roles for HKDC1 under basal conditions; however, such effects may be cell type-specific.</p>
<disp-quote content-type="editor-comment">
<p>(4) The emphasis on glycolysis signatures is confusing, as in the end, glycolysis does not seem to be affected by ZMAT3 status, but mitochondrial respiration is affected. Can the text be clarified to address this? It is also difficult to understand the role of oxygen consumption rate (OCR) in ZMAT3 phenotypes, as it does not fully track with proliferation. For example, ZMAT3 KD has the highest OCR, and the other conditions have similar OCRs but different proliferative rates in Figure 3D. Also, the colors used in Figure 3 to denote different genotypes change between B/C and D, which is confusing.</p>
</disp-quote>
<p>We thank the reviewer for pointing out the inconsistency in the colors of the graph in Figure 2, which we have now corrected. Our data indicates that ZMAT3 regulates mitochondrial respiration without significantly affecting glycolysis. It is possible that mitochondria in ZMAT3-KO cells are oxidizing more substrates that are not produced by glycolysis. Additional work will be required to fully determine these mechanisms. We have clarified this on page 8 of the revised manuscript.</p>
<disp-quote content-type="editor-comment">
<p>(5) The lack of ZMAT3 binding to RNAs in PAR-CLIP is not proof that it does not do so. A more targeted approach should be used, using individual RIP assays. The authors should also analyze the splicing of HKDC1, which could be affected by ZMAT3.</p>
</disp-quote>
<p>As suggested, we performed ZMAT3 RNA IP experiments (RIP) using doxycycline-inducible HCT116-ZMAT3-FLAG cells. However, we did not observe significant enrichment of HKDC1 mRNA in the ZMAT3 IPs (Figure 5 – figure supplement 1A), consistent with previously published ZMAT3 RIP-seq data (Bersani et al, Oncotarget, 2016). These findings further support the notion that ZMAT3 does not directly bind to HKDC1 mRNA in these cells. We Accordingly, we have modified the text on page 10 of the revised manuscript.</p>
<p>In addition, as suggested by the reviewer, we analyzed changes in splicing of HKDC1 pre-mRNA using rMATS in HCT116 cells by comparing our previously published RNA-seq data from siCTRL and siZMAT3-transfected HCT116 cells (Muys et al, Genes Dev, 2021). We focused on splicing events with an FDR &lt; 0.05 and a delta PSI &gt; |0.1| (representing at least a 10% change in splicing). The splicing analysis (data not shown) did not reveal any significant alterations in HKDC1 pre-mRNA splicing upon ZMAT3 knockdown. Corresponding text has been updated on page 10 of the revised manuscript.</p>
<disp-quote content-type="editor-comment">
<p>(6) The authors say that they examine JUN binding at the HKDC1 promoter several times, but they focus on intron 1 in Figure 5. They should revise the text accordingly, and they should also show JUN ChIP data traces for the whole HKDC1 locus in Figure 5C.</p>
</disp-quote>
<p>We thank the reviewer for this helpful suggestion. As recommended, we have revised the text throughout the manuscript and replaced HKDC1 promoter with HKDC1 intron 1 DNA to accurately reflect our analysis, and Figure 5 now shows the JUN ChIP-seq signal across the entire HKDC1 locus.</p>
<disp-quote content-type="editor-comment">
<p>(7) In the ZMAT3 and JUN interaction assays, were these tested in the presence of DNAse or RNAse to determine if nucleic acids mediate the interaction?</p>
</disp-quote>
<p>We thank the reviewer for this valuable suggestion. To test whether nucleic acids mediate the ZMAT3-JUN interaction, we performed ZMAT3 immunoprecipitation (IPs) in the presence or absence of DNase and RNase from doxycycline-inducible ZMAT3-FLAG expressing HCT116 cells. The ZMAT3-JUN interaction was lost upon treatment with either DNase or RNase, indicating that the interaction is mediated by nucleic acids. This data has been added in the revised manuscript (Figure 5-figure supplement 1D and on page 11).</p>
</body>
</sub-article>
</article>